Page last updated: 2024-11-04

probenecid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Probenecid is a medication primarily used to treat gout. It is also used to increase the excretion of certain drugs, such as penicillin and methotrexate. Probenecid works by blocking the reabsorption of uric acid in the kidneys, leading to increased excretion of uric acid in the urine. This reduces the levels of uric acid in the blood, which can help to prevent gout attacks. Probenecid is synthesized in a multi-step process involving the reaction of a benzoyl chloride derivative with a substituted aniline. The compound is important because it provides a therapeutic option for managing gout and enhancing the efficacy of certain medications. It is studied to understand its mechanisms of action, optimize its efficacy, and explore potential new uses. '

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4911
CHEMBL ID897
CHEBI ID8426
SCHEMBL ID3663
MeSH IDM0017601

Synonyms (223)

Synonym
AC-2023
BIDD:GT0626
BIDD:PXR0092
MLS001076472
BRD-K95237249-001-05-9
DIVK1C_000056
KBIO1_000056
4-[(dipropylamino)sulfonyl]benzoic acid
probenid
benemide
robenecid
benzoic acid, 4-((dipropylamino)sulfonyl)-
brn 2815775
4-(n,n-dipropylsulfamoyl)benzoesaeure
probalan
ai3-50078
hsdb 3387
ccris 3643
probenecide [inn-french]
nsc 18786
probenecida [inn-spanish]
einecs 200-344-3
probenecidum [inn-latin]
4-(di-n-propylsulfamoyl)benzoesaeure
SPECTRUM_000834
IDI1_000056
p-(dipropylsulfamyl)benzoic acid
benzoic acid, 4-[(dipropylamino)sulfonyl]-
benzoic acid, p-(dipropylsulfamoyl)-
probecid
probenemid
probexin
benecid
prolongine
benuryl
uricosid
wln: qvr dswn3&3
nsc18786
apurina
probenecid acid
benemid
p-(dipropylsulfamoyl)benzoic acid
4-(dipropylsulfamoyl)benzoic acid
nsc-18786
nci-c56097
tubophan
proben
synergid r
PRESTWICK_809
NCGC00016251-01
cas-57-66-9
PRESTWICK3_000542
BSPBIO_002227
SPECTRUM5_001419
BPBIO1_000643
PRESTWICK2_000542
OPREA1_416955
NCGC00023829-03
AB00052080
C07372
57-66-9
probenecid
DB01032
4-((dipropylamino)sulfonyl)benzoic acid
benemid (tn)
probenecid (jp17/usp/inn)
D00475
NCGC00023829-05
NCGC00023829-04
NCGC00023829-06
smr000058280
MLS000028496 ,
KBIO2_006450
KBIOGR_000971
KBIO3_001727
KBIOSS_001314
KBIO2_001314
KBIO2_003882
SPBIO_001327
PRESTWICK1_000542
SPECTRUM2_001294
SPECTRUM4_000486
NINDS_000056
PRESTWICK0_000542
SPBIO_002504
SPECTRUM3_000554
SPECTRUM1500502
BSPBIO_000583
NCGC00016251-02
HMS2092C03
AKOS000165123
probenecidum
hc 5006
probenate
CHEMBL897 ,
chebi:8426 ,
HMS500C18
bdbm50206509
4-dipropylsulfamoyl-benzoic acid anion
4-dipropylsulfamoyl-benzoic acid
4-dipropylsulfamoyl-benzoic acid(probenecid)
HMS1920J22
HMS1569N05
NCGC00016251-08
NCGC00023829-07
HMS2096N05
HMS3259G04
EN300-69677
dtxcid901188
NCGC00256441-01
dtxsid9021188 ,
tox21_302928
NCGC00259659-01
tox21_202110
nsc-757292
pharmakon1600-01500502
nsc757292
tox21_110328
P1975
4-(n,n-dipropylsulfamoyl)benzoic acid
STL229614
HMS2233N05
S4022
CCG-39232
NCGC00016251-05
NCGC00016251-03
NCGC00016251-06
NCGC00016251-10
NCGC00016251-04
NCGC00016251-07
NCGC00016251-09
probenicid
probenecid [usp:inn:ban:jan]
po572z7917 ,
probenecide
unii-po572z7917
probenecida
probenecid [inn]
probenecid [jan]
probampacin component probenecid
probenecid [usp impurity]
probenecid [mart.]
proben-c component probenecid
probenecid [orange book]
probenecidum [who-ip latin]
colbenemid component probenecid
probenecid [hsdb]
probenecid component of proben-c
probenecid [mi]
probenecid [usp monograph]
probenecid [usp-rs]
probenecid [ep impurity]
probenecid [who-dd]
col-probenecid component probenecid
probenecid [ep monograph]
probenecid component of probampacin
probenecid component of colbenemid
probenecid [who-ip]
probenecid component of col-probenecid
EPITOPE ID:180853
HMS3369L18
gtpl4357
HY-B0545
4-(n,n-dipropylaminosulphonyl)benzoic acid
NC00530
SCHEMBL3663
NCGC00016251-13
tox21_110328_1
Q-201621
colbenemid (salt/mix)
p-(dipropylsulfamoyl) benzoic acid
AB00052080_15
OPERA_ID_677
AB00052080_16
mfcd00038402
SR-01000003108-2
sr-01000003108
probenecid, united states pharmacopeia (usp) reference standard
HMS3652O17
probenecid, european pharmacopoeia (ep) reference standard
SR-01000003108-3
SBI-0051492.P003
HMS3713N05
Z53037954
SW196943-3
benemid; benecid; benuryl
BCP21785
probenecid (benemid)
Q900898
BRD-K95237249-001-15-8
SB17360
STR06053
HMS3885I18
AMY8947
HMS3743E07
D92177
NCGC00016251-17
BP166195
CS-0695004
HY-B0545R
probenecid (standard)
rto ,
probenecidum (inn-latin)
probenecid (usp:inn:ban:jan)
4-(n,n-dipropylsulfamoyl)benzoesaure
4-(di-n-propylsulfamoyl)benzoesaure
probenecid (ep monograph)
prob
probenecid (usp-rs)
probenecida (inn-spanish)
probenecid (usp monograph)
4-(dipropylaminosulfonyl)benzoic acid
4-(dipropylsulfamoyl) benzoic acid
m04ab01
benzoic acid, 4-((dipropylamino)sulfonyl)
probenecid (ep impurity)
nc1-c56097
sk-probenecid
probenecide (inn-french)
probenecid (usp impurity)
probenecid (mart.)
probenate (see under pivampicillin)
probenecide, 1mg/ml in methanol

Research Excerpts

Overview

Probenecid is a well-established drug for the treatment of gout. It is thought to act on an organic anion transporter, thereby affecting uric acid excretion in the kidney by blocking urate reuptake.

ExcerptReferenceRelevance
"Probenecid (Prob) is a well-known FDA-approved therapy for gout owing to its uricosuric effect."( Probenecid ameliorates testosterone-induced benign prostatic hyperplasia: Implications of PGE-2 on ADAM-17/EGFR/ERK1/2 signaling cascade.
Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023
)
3.07
"Probenecid is a classic ATP-binding cassette and solute carrier inhibitor that blocks transport of organic acids, including NAC."( N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury.
Bell, MJ; Clark, RSB; Empey, PE; Kochanek, PM, 2023
)
1.95
"Probenecid is a drug that reduces the urinary excretion of AAS from the body."( The Probenecid-story - A success in the fight against doping through out-of-competition testing.
Hemmersbach, P, 2020
)
1.84
"Probenecid (PROB) is a clinical probe inhibitor of renal organic anion transporter (OAT) 1 and OAT3 that inhibits in vitro activity of hepatic drug transporters OATP1B1 and OATP1B3. "( Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Holenarsipur, VK; Kandoussi, H; Mariappan, TT; Shen, H; Sinz, M; Zeng, J; Zhang, Y, 2020
)
2.23
"Probenecid is a pannexin-1 antagonist and a probenecid therapy was investigated."( Probenecid-treatment reduces demyelination induced by cuprizone feeding.
Becker, P; Beisswenger, C; Hainz, N; Meier, C; Rapp, D; Tschernig, T; Wagenpfeil, S; Wonnenberg, B, 2017
)
2.62
"Probenecid is a well-established drug for the treatment of gout and is thought to act on an organic anion transporter, thereby affecting uric acid excretion in the kidney by blocking urate reuptake. "( Probenecid, a gout remedy, inhibits pannexin 1 channels.
Dahl, G; Locovei, S; Silverman, W, 2008
)
3.23
"Probenecid is a non-selective inhibitor of multidrug resistance-associated proteins, but it also inhibits organic anion transporters."( Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009
)
1.37
"Probenecid is a non-selective inhibitor of multidrug-resistance associated proteins and organic anion transporters thus it can modulate the transport functions in the central nervous system influencing nociception."( Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus.
Fejes, A; Pardutz, A; Tajti, J; Toldi, J; Vamos, E; Vecsei, L, 2009
)
1.39
"Probenecid (PRB) is an agent that reduces the systemic level of uric acid, and has the ability to inhibit the renal tubular secretion of agents that are co-administered with it. "( Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome.
Hara, Y; Hashimoto, Y; Hosoya, T; Ito, H; Miyazaki, Y; Okonogi, H; Utsunomiya, Y, 2010
)
2.19
"Probenecid is an FDA-approved inhibitor of the Multidrug Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans."( Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
Alarcon, S; Berdougo, E; Breslin, PA; Doranz, BJ; Greene, TA; Rucker, JB; Thomas, A, 2011
)
2.53
"Probenecid is a highly lipid soluble benzoic acid derivative originally used to increase serum antibiotic concentrations. "( Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation.
Brokamp, C; Cai, W; Gao, X; Haar, L; Jiang, M; Jones, WK; Koch, SE; Lasko, VM; Liu, Y; Lorenz, JN; Ren, X; Robbins, N; Rubinstein, J; Tranter, M; Varma, P; Wang, HS, 2012
)
3.26
"Probenecid is an uricosuric agent which undergoes extensive hepatic metabolism and whose elimination after high doses may become dose dependent."( Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions.
Pea, F, 2005
)
1.05
"Probenecid is a known substrate for renal glucuronidation."( Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans. A pilot experiment.
van den Biggelaar-Martea, M; van Ewijk-Beneken Kolmer, EW; Verwey-van Wissen, CP; Vree, TB, 1994
)
2.45
"Probenecid was shown to be an uncompetitive inhibitor of paracetamol glucuronidation in vitro, using rat liver microsomes."( The effect of probenecid on paracetamol metabolism and pharmacokinetics.
Kamali, F, 1993
)
1.37
"Probenecid was found to be a weak inhibitor of both components of the UDP-GlcUA uptake."( Two kinetically-distinct components of UDP-glucuronic acid transport in rat liver endoplasmic reticulum.
Battaglia, E; Berg, CL; Drake, RR; Fournel-Gigleux, S; Gollan, JL; Lester, R; Magdalou, J; Mizeracka, M; Nowell, S; Radominska, A, 1996
)
1.02
"Probenecid is an anion channel blocker and uricosuric agent, originally developed to slow the rate of excretion of penicillin. "( Probenecid inhibits platelet responses to aggregating agents in vitro and has a synergistic inhibitory effect with penicillin G.
Kinlough-Rathbone, RL; Packham, MA; Perry, DW; Rand, ML; Ruben, DH, 1996
)
3.18
"Probenecid appeared to be a competitive inhibitor of NMN transport."( Interactions of organic anions with the organic cation transporter in renal BBMV.
Giacomini, KM; Gisclon, LG; Hsyu, PH; Hui, AC, 1988
)
1

Effects

Probenecid is a potent inhibitor of urinary and biliary excretion of anionic compounds mediated by transporters such as organic anion transporter and multidrug resistance-associated protein 2 (Mrp2) It has been shown to delay the plasma clearance of methotrexate in the rat.

ExcerptReferenceRelevance
"Probenecid, which has been safely used clinically for decades in non-cardiac conditions, has recently been identified as an agonist of the transient receptor potential vanilloid 2 channel."( Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial.
Bunke, J; Evans, K; Foster, G; Joseph, J; Luo, X; Mcconeghy, K; Onadeko, T; Parent, M; Robbins, N; Rubinstein, J; Wu, WC, 2022
)
1.82
"Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes. "( Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
Koch, SE; Kranias, EG; Liu, G; McDermott, MR; Onusko, E; Robbins, N; Rubinstein, J, 2020
)
3.44
"Probenecid has moderate efficacy as ULT in clinical management of patients with complex gout who have a lack of efficacy or intolerance to allopurinol. "( Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Dalbeth, N; Gow, PJ; Pui, K, 2013
)
2.12
"Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents. "( Probenecid: an emerging tool for neuroprotection.
Colín-González, AL; Santamaría, A, 2013
)
3.28
"Probenecid has been widely used in the treatment of gout, but evidence suggests that it may also have antinociceptive effects in different inflammatory and pain conditions. "( Effect of probenecid on the pain-related behaviour and morphological markers in orofacial formalin test of the rat.
Bohár, Z; Fejes-Szabó, A; Nagy-Grócz, G; Párdutz, Á; Pődör, B; Tajti, J; Tar, L; Toldi, J; Vámos, E; Vécsei, L, 2015
)
2.26
"Probenecid has been used for decades to treat gout, and recent studies have revealed it is also a specific inhibitor of the pannexin-1 channel. "( Probenecid protects against cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats.
Du, Y; He, F; Luo, B; Peng, G; Wang, J; Wei, R; Xu, Y; Yin, B, 2015
)
3.3
"Probenecid also has been shown to affect ATP release, leading to the suggestion that ATP release involves an organic anion transporter."( Probenecid, a gout remedy, inhibits pannexin 1 channels.
Dahl, G; Locovei, S; Silverman, W, 2008
)
2.51
"Probenecid has been used as a potent inhibitor of urinary and biliary excretion of anionic compounds mediated by transporters such as organic anion transporters and multidrug resistance-associated protein 2 (Mrp2)."( Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion.
Lee, JH; Lee, YJ; Oh, JH; Shin, YJ, 2013
)
1.53
"Probenecid has long been used in the treatment of gout. "( Anti-hypertensive effects of probenecid via inhibition of the α-adrenergic receptor.
Kim, SJ; Park, JB, 2011
)
2.1
"Probenecid has been shown to delay the plasma clearance of methotrexate in the rat and to reduce both hepatic and renal excretion of methotrexate in this animal model. "( Interaction of probenecid with methotrexate transport and release in the isolated rat hepatocyte in suspension.
Gewirtz, DA; Plotkin, JH; Randolph, JK, 1984
)
2.06
"Probenecid has been suggested as a prophylactic treatment of penicillin-induced hypokalemia, the proposed mechanism being that penicillin will be prevented from acting as a nonreabsorbable anion binding potassium and resulting in increased urinary losses. "( Use of probenecid in ticarcillin-induced hypokalemia.
Mittal, VK; Pierce, AK; Priestley, JC, 1980
)
2.16
"Probenecid has been shown to decrease renal and biliary excretion of organic acids. "( Lack of probenecid effect on nonrenal excretion of ceftriaxone in anephric patients.
Audet, PR; Carbone, JJ; Gibson, GA; Morrison, G; Patel, IH; Soni, PP, 1990
)
2.16
"Probenecid has no effect on resting or stimulated cytosolic free Ca2+ levels or on FcR-mediated phagocytosis."( Fura-2 secretion and sequestration in macrophages. A blocker of organic anion transport reveals that these processes occur via a membrane transport system for organic anions.
Di Virgilio, F; Silverstein, SC; Steinberg, TH; Swanson, JA, 1988
)
1

Actions

Probenecid was shown to inhibit the excretion of urine and urinary MPTP N-oxide shortly after MPTP administration, which may directly or indirectly increase the neurotoxic action of MPTP in mice. The probenecid-mediated increase in hepatic and biliary exposure of curcumin suggested that the use of combination drug regimens involving curCumin and modulators of eliminati.

ExcerptReferenceRelevance
"Probenecid did not inhibit folate binding to FR, but inhibited PCFT-mediated transport at endosomal pH, and blocked FRalpha-mediated transport into the cytosol."( A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis.
Campanella, E; Goldman, ID; Low, PS; Min, SH; Wang, Y; Zhao, R, 2009
)
1.07
"Probenecid did not increase the exposure of MTX inside the tumor, but caused a longer half-life of central MTX."( The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
Böhlke, M; Henry, K; Kim, J; Maher, TJ; Sani, SN; Stricker-Krongrad, A, 2010
)
1.08
"The probenecid-mediated increase in hepatic and biliary exposure of curcumin suggested that the use of combination drug regimens involving curcumin and modulators of elimination may be an innovative approach for the therapeutic use of curcumin."( Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats.
Kim, HG; Lee, JH; Lee, YJ; Oh, JH, 2013
)
0.95
"Probenecid is known to inhibit the elimination of several acidic drugs. "( Probenecid-induced changes in the clearance of pranoprofen enantiomers.
Imai, T; Nomura, T; Otagiri, M, 2003
)
3.2
"Probenecid does not inhibit the formation of the acyl glucuronide of F, but inhibits the renal clearance of both compounds."( Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid.
van den Biggelaar-Martea, M; Verwey-van Wissen, CP; Vree, TB, 1994
)
1.19
"8. Probenecid was shown to inhibit the excretion of urine and urinary MPTP N-oxide shortly after MPTP administration, which may directly or indirectly increase the neurotoxic action of MPTP in mice."( Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Crampton, JM; Lau, YS; Trobough, KL; Wilson, JA, 1990
)
1.18
"Probenecid was found to inhibit both kidney binding and toxicity of DCVC."( Dichlorovinyl cysteine (DCVC) in the mouse kidney: tissue-binding and toxicity after glutathione depletion and probenecid treatment.
Bakke, JE; Brandt, I; Darnerud, PO; Feil, VJ, 1989
)
1.21
"Probenecid was used to inhibit outward transport of carboxyfluorescein."( Permeability of the blood-retinal barrier to carboxyfluorescein in eyes with rhegmatogenous retinal detachment.
Pederson, JE; Tsuboi, S, 1987
)
0.99
"Probenecid caused an increase in the 5-HIAA content but produced no change in the 5-HT content of the nucleus basalis of pigeon brain.4."( Acid metabolites of monoamines in avian brain; effects of probenecid and reserpine.
Ahtee, L; Sharman, DF; Vogt, M, 1970
)
1.21

Treatment

Probenecid treatment decreased the urinary excretion of enrofloxacin, whereas enhanced excretion in milk which could be useful in cases of affections of udder in goats. ProbenECid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates.

ExcerptReferenceRelevance
"Probenecid treatment also decreased apoptosis as evidenced by an increase in the level of Bcl-2/Bax."( Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
Koch, SE; Kranias, EG; Liu, G; McDermott, MR; Onusko, E; Robbins, N; Rubinstein, J, 2020
)
2.72
"Probenecid treatment increased ("( Probenecid Inhibits α-Adrenergic Receptor-Mediated Vasoconstriction in the Human Leg Vasculature.
Egelund, J; Gliemann, L; Hellsten, Y; Isakson, BE; Jørgensen, TS; Kiehn, OT; Maagaard, C; Nielsen, MS; Nyberg, M; Piil, P, 2018
)
2.64
"Probenecid treatment resulted in lower disease scores as compared to EAE animals."( Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis.
Hainz, N; Meier, C; Tschernig, T; Wolf, S, 2016
)
2.6
"Probenecid treatment slowed down the decrease in blood BP and simultaneously inhibited its initial rapid excretion in the kidney."( Tetrahydrobiopterin Supplementation: Elevation of Tissue Biopterin Levels Accompanied by a Relative Increase in Dihydrobiopterin in the Blood and the Role of Probenecid-Sensitive Uptake in Scavenging Dihydrobiopterin in the Liver and Kidney of Rats.
Aizawa, S; Harada, T; Hasegawa, H; Naito, M; Ohashi, A; Saeki, Y; Takahashi, T, 2016
)
1.35
"Probenecid pretreatment decreased the urinary excretion of enrofloxacin, whereas enhanced excretion in milk which could be useful in cases of affections of udder in goats."( Effect of probenecid on kinetics of enrofloxacin in lactating goats after subcutaneous administration.
Jayachandran, C; Jha, HN; Kumar, N; Narayan, JP, 2009
)
1.48
"Probenecid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates."( Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009
)
1.37
"probenecid pretreatment. In the topical dosing study, a significant decline in BAPSG delivery was observed in the iris-ciliary body but no significant changes were observed in other tissues of the anterior segment of the eye including tears."( Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.
Ayalasomayajula, SP; DeRuiter, J; Kompella, UB; Sunkara, G, 2010
)
2.52
"Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. "( Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans.
Geisslinger, G; Jarrar, M; Langer, M; Lötsch, J; Schmidt, H; Skarke, C, 2004
)
3.21
"Probenecid treatment prolonged the terminal serum half-life of cephalothin-like activity from 0.52 to 1.0 h, and of cefoxitin from 0.68 to 1.4 h."( Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin.
Goldberg, AD; Goodwin, CS; Martin, CM; Raftery, EB; Skeggs, H; Till, AE, 1974
)
1.26
"Probenecid treatment caused a 65% reduction in the renal clearance (0.426 +/- 0.079 versus 0.165 +/- 0.027 l/h/kg) and a 90% reduction in the tubular secretion clearance (0.275 +/- 0.075 versus 0.0230 +/- 0.0217 l/h/kg), whereas it had no effect on the renal clearance of cimetidine."( Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
Chida, M; Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2006
)
1.27
"Probenecid pretreatment in six patients was without effect on T 1/2 beta and Cl beta."( Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
Blumer, JL; Kercsmar, CM; Murdell, D; Myers, CM; Reed, MD; Stern, RC, 1983
)
0.99
"Probenecid pretreatment attenuated the fall in endocochlear potential seen after furosemide (25 mg/kg i.v.): untreated, 58.6 +/- 27.0 mV; probenecid pretreatment, 14.1 +/- 11.9 mV (P less than .01)."( Probenecid reduces cochlear effects and perilymph penetration of furosemide in chinchilla.
Green, TP; Juhn, SK; Morizono, T; Rybak, LP, 1984
)
2.43
"Probenecid pretreatment increased the ana under the plasma drug concentration-time curve (AUC) two-fold and decreased the total body clearance significantly with decreases in both renal and non-renal clearance."( The effect of probenecid on nafcillin disposition.
Sharanevych, MA; Waller, ES; Yakatan, GJ, 1982
)
1.35
"Probenecid pretreatment increased the hepatic contents of BGD and HBGD and also promoted the effects of these chelating agents in removing Cd from the liver, indicating an inhibitory effect of probenecid on the glucuronidation of BGD and the secretion of HBGD from the kidney."( Mechanism of mobilization of renal and hepatic cadmium by dithiocarbamates in mice.
Funakoshi, T; Kamenosono, T; Kojima, S; Shimada, H, 1994
)
1.01
"4. Probenecid treatment significantly decreased the CLrf,s of both enantiomers, and the extent of inhibition for the (S)(-)-enantiomer (53%) was significantly higher than that for the antipode (14%)."( Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey.
Higaki, K; Kawahara, S; Nakano, M, 1993
)
1
"Probenecid pretreatment increased Cd efflux from the hepatocytes by BGD, but did not affect Cd efflux by HBGD."( Mechanism of mobilization of cadmium by dithiocarbamates in rat primary hepatocyte cultures.
Funakoshi, T; Kado, K; Kojima, S; Ueda, K, 1996
)
1.02
"Probenecid pretreatment significantly (P < 0.05) diminished compound A-induced increases (mean +/- SE) in urine excretion of protein (45.5 +/- 3.8 mg/24 h vs."( Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
Garton, K; Hankins, DC; Kharasch, ED; Kilty, CG; Thorning, D, 1997
)
1.02
"Probenecid pretreatment promoted an elevation in the urinary 16-hr excretion of APAP and a diminution in the plasma levels attained by APAP."( Probenecid protects against In vivo acetaminophen-induced nephrotoxicity in male Wistar rats.
Elías, MM; Monasterolo, LA; Trumper, L, 1998
)
2.46
"Probenecid treatment significantly reduced hippuran clearance (P < 0.003), but RBF was unchanged (P > 0.17)."( Mapping of local renal blood flow with PET and H(2)(15)O.
Alpert, NM; Babich, JW; Correia, DJ; Fischman, AJ; Littman, BH; Rabito, CA; Rubin, NT; Rubin, RH; Tompkins, RG, 2002
)
1.04
"Probenecid pretreatment decreased the renal content of Cd in Cd-MBGD and Cd-BGD treated mice, but it increased the renal content of Cd and decreased the urinary excretion of the metal in Cd-HBGD and Cd-CBGD treated mice."( Structure-effect relationship in the mobilization of cadmium in mice by several dithiocarbamates.
Funakoshi, T; Imamura, Y; Kamenosono, T; Kojima, S; Shimada, H, 2002
)
1.04
"Probenecid pretreatment did not influence the therapeutic response to CDDP when the letter was administered to BDF mice bearing L1210 leukemia."( Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.
Gale, GR; Ross, DA, 1979
)
1.21
"Probenecid pretreatment of the animals prolonged the second phase half-disappearance time of MTX from 5.20 +/- 0.89 to 7.086 +/- 0.23 hours (mean +/- SD)."( Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
Blaschke, T; Fusner, JE; Glaubiger, DL; Ramu, A, 1978
)
2.42
"Probenecid pretreatment induced significant reductions in renal clearance of furosemide by 78%, the extrarenal clearance by 56%, and the volume of distribution by 52%."( Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.
Branch, RA; Homeida, M; Roberts, C, 1977
)
1.35
"Probenecid-treated rats received a loading dose of probenecid followed by an i.v."( Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux.
Anderson, BD; Flaharty, KK; Galinsky, RE; Hoesterey, BL, 1991
)
2.45
"3. Probenecid pretreatment significantly decreased the renal excretion of piretanide in all subjects and consistently decreased the natriuretic response with the exception of intravenous piretanide challenge in subjects not undergoing fluid replacement."( Analysis of the natriuretic action of a loop diuretic, piretanide, in man.
Lant, AF; Noormohamed, FH, 1991
)
0.8
"Probenecid pretreatment reduced the overall urinary recovery of piretanide without altering the i.v./oral differences."( Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
Dixey, JJ; Lant, AF; McNabb, WR; Noormohamed, FH, 1990
)
1.21
"Probenecid treatment increased several fold both conjugated 5-HTOL and 5-HIAA levels in brain tissue."( 5-Hydroxytryptophol and 5-hydroxyindoleacetic acid levels in rat brain: effects of various drugs affecting serotonergic transmitter mechanisms.
Beck, O; Jonsson, G; Lundman, A, 1987
)
0.99
"Probenecid pretreatment will also cause a decrease in the onset time of midazolam."( Influence of plasma proteins on the onset of hypnotic action of intravenous midazolam.
Collier, PS; Dundee, JW; Halliday, NJ; Harper, KW; Loughran, PG, 1985
)
0.99
"Probenecid pretreatment led to a reduction in Tris-BP and Bis-BP tubular necrosis, these effects may be related to inhibition of Bis-BP uptake in the kidney."( Nephrotoxicity of selectively deuterated and methylated analogues of Tris-BP and Bis-BP in the rat.
Dahl, JE; Dybing, E; Nelson, SD; Omichinski, JG; Søderlund, EJ, 1988
)
1
"In probenecid-treated animals, argon laser photocoagulation did not affect the permeability of the blood-retinal barrier."( Effect of argon laser photocoagulation on the permeability of the blood-retinal barrier.
Kondo, T; Miura, M; Ogura, Y; Tsukahara, Y, 1987
)
0.79
"Probenecid pretreatment decreased both urine volume (P = 0.0016) and sodium excretion (P = 0.0003), implying that delivery of drug to the urinary side of the nephron is the major determinant of response."( Clinical pharmacology of torasemide, a new loop diuretic.
Anderson, SA; Brater, DC; Leinfelder, J, 1987
)
0.99
"Probenecid pretreatment did not decrease the toxicity of BH4."( The toxicity of tetrahydrobiopterin: acute and subchronic studies in mice.
Combs, AB; Folkers, K; Lewandowski, EM, 1986
)
0.99
"Oral treatment with probenecid - 500 mg per day for one week, then 500 mg twice daily [1000 mg total] per day for three weeks."( Proteomic insight of seminal plasma in spinal cord injured men submitted to oral probenecid treatment for improved motility.
Aballa, TC; Bertolla, RP; Brackett, NL; Camargo, M; Cardozo, KHM; Carvalho, VM; Ibrahim, E; Lynne, CM, 2021
)
1.17
"Oral treatment with probenecid is able to alter the seminal plasma proteome, in pathways that explain decreased innate immune response."( Proteomic insight of seminal plasma in spinal cord injured men submitted to oral probenecid treatment for improved motility.
Aballa, TC; Bertolla, RP; Brackett, NL; Camargo, M; Cardozo, KHM; Carvalho, VM; Ibrahim, E; Lynne, CM, 2021
)
1.17
"Co-treatment with probenecid enhanced BP effects on cell viability, IPP/ApppI accumulation as measurable in MCF-7 and T47D cells, caspase 3/7 activity and target gene expression."( Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014
)
2.17
"Pretreated with probenecid, the systemic exposure of GB was significantly elevated from 8.319 ± 1.646 to 14.75 ± 1.328 µg · mL(-1) ∙h but with reduced total clearance from 1.17 ± 0.331 to 0.596 ± 0.0573 L · h(-1) ∙kg(-1) accompanying no changes in plasma elimination half-lives compared with control group."( The potential drug-drug interactions of ginkgolide B mediated by renal transporters.
Chen, X; Dai, Y; Jiang, W; Li, N; Qiu, Z; Ren, W; Wang, L, 2015
)
0.75
"Treatment with probenecid, an inhibitor for both Mrps and Oatps, significantly increased DNP-SG concentrations in the brain, heart, liver, kidney, jejunum, spleen and skeletal muscle as compared with those in control rats, suggesting the expression of some probenecid-sensitive efflux transporters in these tissues."( Modulated function of tissue efflux transporters under hyperbilirubinemia in rats.
Mori, N; Murakami, T; Yokooji, T, 2010
)
0.7
"Treatment with probenecid prevented increased plasma creatinine and tubulointerstitial injuries, and reduced both the extent and the severity of ultrastructural lesions induced by aristolochic acid, such as the loss of brush border, mitochondrial edema, and the disappearance of mitochondrial crests."( Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy.
Antoine, MH; Arlt, VM; Baudoux, TE; De Prez, EG; Goujon, JM; Nortier, JL; Pozdzik, AA; Quellard, N, 2012
)
2.16
"Pretreatment with probenecid significantly elevated levels of AZL in both serum and bone while increasing the half-life in serum from 0.44 to 0.65 h."( Azlocillin and cefonicid penetration into bone enhanced by probenecid.
Harrod, LG; Raff, MJ; Summersgill, JT, 1984
)
0.83
"Pretreatment with probenecid caused a significant decrease in paracetamol clearance (6.23 to 3.42 ml.min-1.kg-1)."( The effect of probenecid on paracetamol metabolism and pharmacokinetics.
Kamali, F, 1993
)
0.97
"Pretreatment with probenecid did not affect the plasma concentrations of the oxprenolol enantiomers, but there was a slight decrease in their urinary excretion."( Effect of probenecid on the enantioselective pharmacokinetics of oxprenolol and its glucuronides in the rabbit.
Belpaire, FM; Bogaert, MG; Laethem, ME; Wijnant, P, 1995
)
1.02
"Treatment with probenecid and intra-arterial injection of reserpine resulted in considerable improvement."( Treatment of calcinosis circumscripta and Raynaud's phenomenon.
Meyers, D, 1976
)
0.6
"Pretreatment with probenecid (0.5 or 1.0 mmol/kg, i.p.) reduced the renal methylmercury accumulation 30 min after CH3HgCl injection in a dose-dependent manner in both ureter-ligated and sham-operated mice."( Routes for renal transport of methylmercury in mice.
Imura, N; Naganuma, A; Tanaka, T, 1992
)
0.61
"Pretreatment with probenecid resulted in a prominent decrease in urinary sodium excretion (246 +/- 25 mmol/24 hr for muzolimine alone 161 +/- 24 mmol/24 hr for muzolimine and probenecid; p less than 0.01)."( Muzolimine: renal site of action and interaction with probenecid in humans.
Lant, AF; Noormohamed, FH, 1991
)
0.85
"Pretreatment with probenecid results in a higher concentration on the peritubular or blood side of the tubules and these results lead us to question the unconditional acceptance of a luminal site of action for the loop diuretics."( The influence of co-administered organic acids on the kinetics and dynamics of frusemide.
Meyer, EC; Moncrieff, J; Sommers, DK, 1991
)
0.6
"Pretreatment with probenecid prevented the inhibition of the gamma-glutamyl transferase activity due to CEC in BBM, but failed to do so for the Na+,K(+)-ATPase activity in BLM vesicles."( Effect of S-(2-chloroethyl)-DL-cysteine on the transport of p-aminohippurate ion in renal plasma membrane vesicles.
Chakrabarti, S; Côté, MG; Guo, WX; Malick, MA, 1990
)
0.6
"Pretreatment with probenecid produced significant increases in absolute peak and plasma diuretic concentrations, t1/2 and mean residence time while decreasing steady-state volume of distribution, total clearance, renal clearance and fraction of unchanged drug excreted without affecting the bioavailability of piretanide."( Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
Dixey, JJ; Lant, AF; McNabb, WR; Noormohamed, FH, 1990
)
0.81
"Treatment with probenecid (200 mg/kg i.p.) caused an increase of both metabolites in the CSF."( Repeated determination of cerebrospinal fluid amine metabolites by automated direct sampling from an implanted cannula in freely moving rats.
De La Riva, CF; Yeo, JA, 1985
)
0.61
"Treatment with probenecid and p-aminohippuric acid, potent competitive inhibitors for the renal anionic transport system, caused a profound decrease in the renal clearance of enalaprilat to the level of GFR."( Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
Chen, IW; Duggan, DE; Lin, JH; Ulm, EH,
)
0.47
"Pretreatment with probenecid (240 mg kg-1 body weight) potentiated the hyperglycaemic effect of frusemide (25 or 200 mg kg-1 body weight)."( Probenecid potentiates the hyperglycaemic effect but reduces the diuretic effect of frusemide in mice.
Sandström, PE, 1986
)
2.04
"Pretreatment with probenecid (PBC) led to a doubling of the serum MTX level and a significant increase in the area under the concentration-time curve."( Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.
Lilly, MB; Omura, GA, 1985
)
0.82
"Treatment with probenecid did not affect pharmacokinetic values of cefazolin."( Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
Ashcraft, SM; Donecker, JM; Sams, RA, 1986
)
0.93
"Pretreatment with probenecid prolonged the elimination half-life in both rats and dogs."( Pharmacokinetics of Sch 34343 in rats and dogs.
Chung, M; D'Souza, R; Kim, H; Korduba, C; Lim, J; Lin, C; Loebenberg, D; Moss, E; Oden, E; Veals, J, 1985
)
0.59
"When treatment with probenecid led to renal cortical concentrations of less than 120 nmol eq HCBD-NAC/g and an amount of covalently bound material less than 0.4 nmol eq/mg protein the animals were completely protected against the nephrotoxicity, as assessed by plasma urea and histopathological examination 24 hr after dosing."( Effect of the organic acid transport inhibitor probenecid on renal cortical uptake and proximal tubular toxicity of hexachloro-1,3-butadiene and its conjugates.
Ishmael, J; Lock, EA, 1985
)
0.84

Toxicity

Probenecid, when administered to F344 rats 1 hour prior to an iv LD50 dose of cis-dichlorodiammineplatinum(II) (CDPP), reduced significantly the peak BUN and serum creatinine levels which occurred 4 days following CDDP.

ExcerptReferenceRelevance
" Overall, adverse reactions characterized as probably drug-related or questinably drug-related were reported in 28% of patients treated with tienilic acid, 24% treated with hydrochlorothiazide, 25% of patients treated with probenecid and 33% treated with placebo."( Safety of tienilic acid.
Beg, MA; Ragland, R, 1979
)
0.44
"Probenecid, when administered sc to F344 rats 1 hour prior to an iv LD50 dose of cis-dichlorodiammineplatinum(II) (CDPP), reduced significantly the peak BUN and serum creatinine levels which occurred 4 days following CDDP."( Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.
Gale, GR; Ross, DA, 1979
)
1.94
" Early studies by several investigators demonstrated that similar compounds such as alpha, beta-unsaturated aldehyde-cysteine adducts have toxic (carcinostatic) activity against Ehrlich ascites tumor cells implanted in mice."( Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat.
Horvath, JJ; Witmer, CM; Witz, G, 1992
)
0.28
"The acute toxic effects of thiabendazole [2-(4'-thiazolyl)benzimidazole; TBZ] on the kidneys of ICR mice were investigated."( Acute renal toxicity of thiabendazole (TBZ) in ICR mice.
Fujitani, T; Tada, Y; Yoneyama, M, 1992
)
0.28
" The cytotoxicity of the cysteine-S-conjugates and mercapturates of TFE and CTFE was similar, but the cysteine-S-conjugates of DCDFE and DBDFE were more toxic than their mercapturates."( Toxicity of the cysteine-S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney. Uptake of the conjugates and activation to toxic metabolites.
Boogaard, PJ; Commandeur, JN; Mulder, GJ; Nagelkerke, JF; Vermeulen, NP, 1989
)
0.28
" An LD50 of approximately 260 mg/kg was obtained from acute (14-day) intraperitoneal survival studies."( The toxicity of tetrahydrobiopterin: acute and subchronic studies in mice.
Combs, AB; Folkers, K; Lewandowski, EM, 1986
)
0.27
" We have recently reported that a glutathione conjugate of PAP, 4-amino-3-S-glutathionylphenol, is more toxic to the kidney than the parent compound itself."( Effect of ascorbic acid, acivicin and probenecid on the nephrotoxicity of 4-aminophenol in the Fischer 344 rat.
Foster, JR; Fowler, LM; Lock, EA, 1993
)
0.56
" KYNA antagonizes the toxic action of quinolinic acid (QUIN), an endogenous NMDA receptor agonist."( Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats.
Altagracia, M; González-Reynoso, L; Kravzov, J; Ordaz-Moreno, J; Ríos, C; Santamaría, A; Solís-Hernández, F, 1996
)
0.59
" The toxic process might also be mediated by glutathione (GSH) conjugates of ADCP, as suggested for the mechanism of 4-aminophenol nephrotoxicity."( 4-Amino-2,6-dichlorophenol nephrotoxicity in the Fischer 344 rat: protection by ascorbic acid, AT-125, and aminooxyacetic acid.
Anestis, DK; Ball, JG; Brown, PI; Hong, SK; Rankin, GO; Valentovic, MA, 1997
)
0.3
" Dose-dependent asymptomatic proteinuria (39%) and serum creatinine elevation (24%) were the most common adverse events thought to be related to cidofovir."( Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS.
Hardy, WD; Holland, GN; Ives, DV; Jaffe, HS; Johnson, M; Kemper, CA; Kramer, F; Kuppermann, BD; Lalezari, JP; Lewis, RA; McKinley, GF; Nelson, R; Northfelt, DW; Ruby, AE; Simon, GL; Stagg, RJ; Weinberg, DV; Wolitz, RA; Youle, M, 1998
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" In this work we investigated the effect that a systemic administration of L-KYN+PROB exerted on the toxic model induced by 6-OHDA in rats."( Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.
Carrillo-Mora, P; Colín-Barenque, L; García, E; González-Herrera, IG; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Santamaría, A; Silva-Adaya, D; Villeda-Hernández, J,
)
0.4
"Nephrotoxicity is a common and often clinically relevant adverse drug reaction."( [Drug-drug interactions and nephrotoxicity].
Czock, D; Keller, F, 2011
)
0.37
" Dosage adjustment appears to be an efficient and safe way to manipulate systemic exposure to tanshinol."( Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions.
Dong, J; Du, F; Jia, W; Jiang, R; Li, C; Li, L; Liu, X; Olaleye, OE; Wang, F; Xu, F; Yang, J, 2015
)
0.42
"This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients."( Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023
)
0.91

Pharmacokinetics

There was an increase in the mean AUC of indomethacin in plasma when probenecid was given. Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1 to 2. The terminal half-life of AZT was slightly longer during probenemid administration.

ExcerptReferenceRelevance
" There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin."( The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.
Baber, N; Halliday, L; Littler, T; Orme, ML; Sibeon, R, 1978
)
0.73
"Cinoxacin is a new synthetic organic antibacterial compound which has a serum half-life of approximately 1 hour."( Cinoxacin: pharmacokinetics and the effect of probenecid.
Black, HR; Brier, GL; Brunson, MK; Israel, KS; Nash, JF; Nelson, RL; Wolney, JD, 1978
)
0.52
" The antibiotic had a mean terminal serum half-life of 60 to 80 min after the intramuscular doses and 36 to 63 min after intravenous administrations, depending on the dose."( Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.
De Schepper, PJ; Mullie, A; Tjandramaga, TB; Verbesselt, R; Verbist, L, 1978
)
0.26
"The purpose of this article is to review and summarise those aspects of the pharmacokinetic behaviour of the penicillins that may be of particular interest to the clinician."( Pharmacokinetics of the penicillins in man.
Barza, M; Weinstein, L, 1976
)
0.26
" The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11."( Cefuroxime: human pharmacokinetics..
Foord, RD, 1976
)
0.26
"The pharmacokinetic characteristics of ticarcillin, a semisynthetic penicillin more active than carbenicillin against Pseudomonas, were compared to those of carbenicillin in 12 healthy volunteers."( Ticarcillin vs carbenicillin: clinical pharmacokinetics.
Clarke, JT; Kirby, WM; Libke, RD; Luthy, RP; Ralph, ED, 1975
)
0.25
" The pharmacokinetic parameters and the urinary excretion of DPP did not change significantly with the dose."( Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline.
Apichartpichean, R; Hasegawa, T; Nabeshima, T; Nadai, M, 1992
)
0.56
"Plasma concentrations and renal excretion rates of drugs are measured and renal clearance is calculated in a series of selected pharmacokinetic studies in healthy human volunteers (some studies were conducted in the authors' laboratory and others were reported in the literature)."( Contribution of the human kidney to the metabolic clearance of drugs.
Anderson, PG; Hekster, YA; Vree, TB, 1992
)
0.28
" The means and variances of the pharmacokinetic parameters of the cis and trans isomers of cefprozil were similar in fasting subjects and were affected in a parallel manner by food, metoclopramide, propantheline, and probenecid."( Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.
Barbhaiya, RH; Pittman, KA; Shukla, UA, 1992
)
0.69
" Postinfusion data showed that the zidovudine terminal half-life during high-dose probenecid treatment was longer than that with low-dose probenecid treatment (58."( Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration.
Hedaya, MA; Sawchuk, RJ; Wong, SL, 1992
)
0.76
" Significant difference was not apparent in the pharmacokinetic values of flunixin meglumine with and without concurrent probenecid administration."( Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares.
Brown, MP; Gronwall, R; Merritt, K; Zertuche, JM, 1992
)
0.89
" In adults, the Cmax following administration of the suspension or solution formulations is higher than that achieved following administration of the capsule formulation, and the time to reach peak concentration (Tmax) is increased when loracarbef is administered as a capsule; however, the area under the curve, plasma half-life, and percentage of oral dose excreted in the urine are comparable among all formulations."( Pharmacokinetic profile of loracarbef.
DeSante, KA; Zeckel, ML, 1992
)
0.28
" Non-compartmental methods were used to obtain pharmacokinetic parameters for AZT and AZTG."( Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys.
Finco, TS; Gallo, JM; Mehta, M; Qian, MX; Viswanathan, CT, 1991
)
0.52
" Pharmacokinetic parameters were estimated by model-independent methods."( Probenecid pharmacokinetics in cystic fibrosis.
de Groot, R; Ramsey, B; Smith, A; Weber, A; Williams-Warren, J, 1991
)
1.72
" The cardiac glycoside digoxin is subject to a number of pharmacokinetic interactions."( No effect of probenecid on the renal and biliary clearances of digoxin in man.
Angelin, B; Arvidsson, A; Dahlqvist, R; Hedman, A, 1991
)
0.65
" Blood and urine samples were obtained and pharmacokinetic parameters of procainamide were determined in each treatment period."( Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide.
Boyd, RA; Chang, D; Chin, SK; Giacomini, KM; Lam, YW, 1991
)
0.68
" The half-life of 5-hydroxydantrolene was shorter than that of the parent drug as demonstrated by administration of the metabolite."( Pharmacokinetics of intravenously administered dantrolene and its 5-hydroxy metabolite in dogs.
Van Der Kleijn, E; Vree, TB; Wuis, EW, 1990
)
0.28
"The pharmacokinetic and pharmacodynamic profiles of oral enalapril (20 mg), in absence and in presence of probenecid pretreatment (1 g twice daily for 5 days), were investigated in 12 healthy volunteers on normal salt intake (150 mmol/24 hr)."( Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment.
Lant, AF; McNabb, WR; Noormohamed, FH, 1990
)
0.72
" In order to determine the endoplasmatic reticulum enzyme function, 6-beta-hydroxycortisol excretion and antipyrine pharmacokinetic parameters were evaluated."( Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam.
Brockmeyer, NH; Goos, M; Klimek, K; Mertins, L; Ohnhaus, EE, 1990
)
0.55
" The terminal half-life of AZT was slightly longer during probenecid administration."( Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers.
Elmquist, WF; Hedaya, MA; Sawchuk, RJ, 1990
)
1.97
"The anti-human immunodeficiency virus drug zidovudine is metabolized extensively in human beings to the 5'-glucuronide (GAZT) and is cleared rapidly, resulting in a short half-life and the need for frequent dosing."( Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex.
Blum, MR; Broder, S; de Miranda, P; Good, SS; Myers, CE; Thomas, RV; Yarchoan, R, 1989
)
0.54
"Ceftazidime pharmacokinetic values were studied in unweaned calves given the antibiotic alone or in combination with probenecid."( Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.72
" The elimination half-life (t1/2) was 69."( Probenecid effect on cefuroxime pharmacokinetics in calves.
Kokue, EI; Soback, S; Ziv, G, 1989
)
1.72
" Pharmacokinetic analysis revealed that tubular secretion is the predominant route of excretion, and that secretion is inhibited by probenecid."( Physiologically based pharmacokinetic model for the renal clearance of iodopyracet and the interaction with probenecid in the dog.
Russel, FG; Van Ginneken, CA; Wouterse, AC,
)
0.55
"05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1."( Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.
Adams, WJ; Cathcart, KS; Griffith, DL; Ko, H; Peters, GR, 1989
)
0.5
" There were no significant differences between the pharmacokinetic variables calculated by statistical moment theory or compartmental analysis indicating central compartment output of cefoperazone."( Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.28
" Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e."( Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Dell, D; Lücker, PW; Partos, C; Portmann, R; Suter, K; Weidekamm, E, 1987
)
0.27
" Pharmacokinetic analysis revealed that tubular secretion is the predominant route of excretion, and that secretion is inhibited by probenecid and SUA."( Physiologically based pharmacokinetic model for the renal clearance of phenolsulfonphthalein and the interaction with probenecid and salicyluric acid in the dog.
Russel, FG; van Ginneken, CA; Wouterse, AC, 1987
)
0.69
"The pharmacokinetic properties of lenampicillin (KBT-1585), a new ampicillin ester, were investigated in 41 healthy volunteers."( Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers.
Nakashima, M; Saito, A, 1986
)
0.27
" The total body clearance of MTX was reduced, while the elimination half-life and the drug distribution to the peripheral body compartments were unchanged."( Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits.
Brasch, H; Iven, H, 1986
)
0.27
" Probenecid given IV was characterized by a rapid disposition phase with a mean half-life of 14."( Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
Ashcraft, SM; Donecker, JM; Sams, RA, 1986
)
1.5
" Following both routes of drug administration, the elimination of half-life (T 1/2 beta) was 7 min in rats and 25-32 min in dogs."( Pharmacokinetics of Sch 34343 in rats and dogs.
Chung, M; D'Souza, R; Kim, H; Korduba, C; Lim, J; Lin, C; Loebenberg, D; Moss, E; Oden, E; Veals, J, 1985
)
0.27
" The half-life of BL-P1654 (2."( Human pharmacokinetics of BL-P1654 compared with ampicillin.
Clarke, JT; Kirby, WM; Libke, RD; Luthy, RP; Ralph, ED, 1974
)
0.25
" The results indicate that reduced renal mass increased the plasma half-life for cefotaxime as well as increasing its diffusion into tissue."( Pharmacokinetics of cefotaxime and probenecid in sheep with normal and reduced renal function.
Bourne, DW; Cao, GR; English, PB; Filippich, LJ; Guerrini, VH, 1984
)
0.54
" The data were fit by iterative nonlinear regression procedures to a two-compartment open pharmacokinetic model, with elimination from the central compartment."( Effect of probenecid on the pharmacokinetics of cefmenoxime.
Quinn, D; Rollins, DE; Sennello, LT; Sonders, RC; Tolman, KG, 1983
)
0.67
" The ultimate half-life t 1/2 of mezlocillin (46."( [Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)].
de Schepper, PJ; Tjandramaga, TB; Verbesselt, R; Verbist, L, 1982
)
0.49
"The pharmacokinetic profile of bromophenol blue (I) in the plasma, urine, and bile of beagle dogs was determined after intravenous administration of 5-, 20-, and 30-mg/kg doses."( Dose-dependent pharmacokinetics and hepatobiliary transport of bromophenol blue in the beagle.
Pearlman, RS; Wills, RJ; Yakatan, GJ, 1984
)
0.27
" The plasma half-life of N-formimidoyl thienamycin was slightly less than 1 h and did not increase significantly with the coadministration of probenecid."( Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
Alestig, K; Ferber, F; Huber, JL; Jones, KH; Kahan, FM; Meisinger, MA; Norrby, SR; Rogers, JD, 1983
)
0.47
" Co-administration of imipenem with probenecid resulted in a slight but significant increase of the plasma half life and a corresponding increase of the area under the plasma concentration curve (AUC)."( Pharmacokinetics of imipenem in healthy volunteers.
Björnegård, B; Ferber, F; Jones, KH; Norrby, SR, 1983
)
0.54
"The effects of probenecid on the pharmacokinetic parameters of cefadroxil administered in a single dose of 500 mg are studied."( The pharmacokinetics of cefadroxil associated with probenecid.
Dominguez-Gil, A; Mariño, EL, 1981
)
0.87
" Statistical analysis showed that probenecid had no significant effect on any of the pharmacokinetic parameters measured."( Effect of probenecid on the pharmacokinetics of aminophylline.
Chen, TW; Patton, TF, 1983
)
0.95
" After intravenous bolus injection of 15 and 30 mg/kg doses, pharmacokinetic data were calculated, using a two-compartment open body model."( Pharmacokinetics of azlocillin in healthy subjects.
Fillastre, JP; Humbert, G; Leroy, A, 1981
)
0.26
" Total body clearance (Cltot) and half-life are dependent on renal function as evaluated by estimated creatinine clearance (Clcr)."( Overview of acyclovir pharmacokinetic disposition in adults and children.
Blum, MR; de Miranda, P; Liao, SH, 1982
)
0.26
"05), and an 18% increase in the terminal plasma half-life (2."( Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans.
de Miranda, P; King, DH; Laskin, OL; Lietman, PS; Longstreth, JA; Page, DA; Rocco, L, 1982
)
0.65
" Serum samples were analysed by the chemical method for penicillin and the data subjected to pharmacokinetic analysis using a two compartment open model."( Pharmacokinetics of ticarcillin in man.
Davies, BE; Humphrey, MJ; Langley, PF; Lees, L; Legg, B; Wadds, GA, 1982
)
0.26
" 4 Pharmacokinetic analyses indicated significant changes only in the parameters associated with renal excretion of drugs."( The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers.
Bullock, DW; Bywater, MJ; Holt, HA; Reeves, DS; Thornhill, DP; White, LO, 1981
)
0.62
" Therefore this study evaluated potential pharmacokinetic interactions between ceftiofur sodium and aspirin."( The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid.
Freeman, DA; Hanlon, D; Parton, K; Whittem, T, 1995
)
0.49
" The preclinical development included pharmacokinetic and toxicological investigations in mice, rats, and dogs."( Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
Dalgaard, L; Hjortkjaer, RK; Nordholm, L; Regnier, B,
)
0.33
" A pharmacokinetic profile of furosemide is shown, and some preliminary pharmacokinetic parameters of furosemide obtained from one human volunteer are given."( Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid.
van den Biggelaar-Martea, M; Verwey-van Wissen, CP; Vree, TB, 1994
)
0.47
" Cmax was increased significantly when tenoxicam was given with probenecid (2."( Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
Day, RO; Geisslinger, G; Paull, P; Williams, KM, 1994
)
0.84
"0 mg/kg body weight, the pharmacokinetic parameters Clt, Clr, elimination-rate constant and apparent volume of distribution at steady state were not statistically different between doses."( Renal clearance of domoic acid in the rat.
Hierlihy, SL; Suzuki, CA, 1993
)
0.29
" A pharmacokinetic profile of indomethacin is shown, and some preliminary pharmacokinetic parameters of indomethacin obtained from one human volunteer are given."( Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid.
van den Biggelaar-Martea, M; Verwey-van Wissen, CP; Vree, TB, 1993
)
0.47
" In this randomized, crossover evaluation in healthy volunteers, probenecid reduces the renal clearance of allopurinol riboside, extends the half-life of allopurinol riboside in plasma, and triples the levels of allopurinol riboside in plasma."( Effects of probenecid on the pharmacokinetics of allopurinol riboside.
Shapiro, TA; Were, JB, 1993
)
0.91
" The elimination half-life was 7 to 8 h, independently of the doses."( Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
Ishida, R; Kosuge, K; Kusajima, H; Masuda, Y; Nakashima, M; Ooie, T; Uchida, H; Uematsu, T, 1995
)
0.29
" Concentrations of cidofovir in kidney declined with a half-life of 23 hr and were > 1,000-fold higher than plasma levels by 120 hr."( Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.
Cundy, KC; Hitchcock, MJ; Lee, WA; Li, ZH, 1996
)
0.29
" A multicenter, open-label, randomized, crossover pharmacokinetic study with four phases was undertaken at an outpatient private research center and at university research clinics."( Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Casserella, S; Cimoch, PJ; Griffy, KG; Jung, D; Lavelle, J; Pollard, R; Tarnowski, TL; Wong, R, 1998
)
0.52
" Pharmacokinetic parameters were characterized with RSTRIP, an iterative, nonlinear, weighted, least-squares-regression program."( Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.
Drusano, G; Liu, QF; Liu, W; Louie, A; Madu, A; Mayers, M; Mian, U; Miller, MH; Perkins, R, 1998
)
0.3
" Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies."( Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy, KC, 1999
)
0.3
" The plasma concentration-time data for both enrofloxacin and ciprofloxacin were best described by a one-compartment open pharmacokinetic model."( Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
Ahmad, AH; Malik, JK; Ramesh, S; Rao, GS; Sharma, LD; Tripathi, HC, 2002
)
0.52
" Average key pharmacokinetic parameters (Cmax, tmax, lambda z, AUC0-infinity, Vss, CL, CLR, fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data."( Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis.
Duncan, BA; Ingrosso, A; Mucci, M; Nickens, DJ; Rodríguez, CA; Wolf, DL, 2003
)
0.55
" No changes in any plasma pharmacokinetic parameters of fexofenadine were found during cimetidine treatment."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.56
" Finally, we tested several pharmacokinetic models, assuming first-order or capacity-limited processes at each brain interface, to describe experimental morphine and M6G concentrations previously obtained in rat plasma and brain fluids."( Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.
Bourasset, F; Scherrmann, JM, 2006
)
0.33
" The prolonged biological half-life and decreased Vdss decreased Clp significantly."( Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs.
Daniel, GB; Hashimoto, M; Ito, N; Kakizaki, T; Natsuhori, M; Sato, K; Yamada, N; Yokoyama, Y, 2005
)
0.6
"07 l/kg, elimination half-life was 18 +/- 6 hr, and mean residence time (MRT) was 23 +/- 6 hr."( Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs.
Ito, N; Kakizaki, T; Karasawa, A; Kubo, S; Natsuhori, M; Yamada, N; Yokoyama, Y, 2006
)
1.78
" Consistent with the prediction that reduced GHB brain concentrations could translate to decreased pharmacodynamic effects, a pilot study in rats showed that the pronounced GHB sedative/hypnotic effects (24."( Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.
Bhattacharya, I; Boje, KM, 2006
)
0.33
" Pharmacokinetic and pharmacodynamic parameters were analysed using two-way ANOVA."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
0.58
" The aims of this study were to elucidate its pharmacokinetic characteristics, tissue distribution, plasma protein binding and excretion properties and underlying mechanisms of deuxemether in rats based on the simultaneous determination of MHD and DMD."( Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether.
Hao, H; He, H; Li, X; Wang, G; Wang, R; Wang, W; Xie, H; Xu, M, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" to rats with or without probenecid (50 mg/kg) or cimetidine (40 mg/kg), and pharmacokinetic parameters were compared."( Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.
Aoki, T; Hashimoto, T; Kamimura, H; Minematsu, T; Usui, T, 2008
)
0.65
" Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day."( Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Beringer, PM; Burckart, GJ; Hidayat, L; Liu, S; Louie, S; Rao, AP; Shapiro, B, 2008
)
1.98
" To investigate this proposal, we developed a population pharmacokinetic model and simulated the pharmacokinetics of candidate combination regimens of oral oseltamivir (45 mg and 30 mg twice a day) plus oral probenecid (500 mg/6 hourly)."( Population pharmacokinetics of oseltamivir when coadministered with probenecid.
Boak, LM; Chanu, P; Gieschke, R; Jonsson, EN; Rayner, CR, 2008
)
0.77
" Pharmacokinetic data, obtained by noncompartmental methods, and safety data are reported."( Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008
)
0.59
"Single-center, prospective, open-label, randomized, three-part crossover pharmacokinetic study."( Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X, 2008
)
0.35
" Probenecid did not increase the exposure of MTX inside the tumor, but caused a longer half-life of central MTX."( The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
Böhlke, M; Henry, K; Kim, J; Maher, TJ; Sani, SN; Stricker-Krongrad, A, 2010
)
1.27
"The aim of this study was to assess and compare the pharmacokinetic (PK) properties, bioavailability, and bioequivalence of a newly developed dispersible tablet formulation (test) of ampicillin/ probenecid with those of an established branded capsule formulation (reference) in healthy Chinese male volunteers."( Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers.
Feng, W; Liu, M; Wang, S; Wei, M; Wu, H; Yao, W; Zhao, H, 2010
)
0.76
" In 4 of the 12 patients studied, kel decreased and the biological half-life (t1/2) of MZR was prolonged when co-administered with PRB, in comparison with the values when MZR was used alone, thus revealing that the PK of MZR was influenced by PRB."( Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome.
Hara, Y; Hashimoto, Y; Hosoya, T; Ito, H; Miyazaki, Y; Okonogi, H; Utsunomiya, Y, 2010
)
0.75
"To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
0.83
"A one compartment pharmacokinetic model with first order absorption best described the oxypurinol concentration-time data."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
0.38
"In conclusion, this first established pharmacokinetic model provides a tool to achieve target oxypurinol plasma concentrations, thereby optimizing the effectiveness and safety of allopurinol therapy in gouty patients with various degrees of renal impairment."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
0.38
"AUC∞ and Cmax of dalcetrapib thiol were increased by 14% and 21%, respectively, by co-administration of probenecid."( In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics.
Aceves Baldó, P; Anzures-Cabrera, J; Bentley, D, 2013
)
0.83
" The objective of this study was to use physiologically based pharmacokinetic (PBPK) modelling to evaluate the effects of patient factors on kidney transporters."( Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations.
Berglund, EG; de L T Vieira, M; Giacomini, KM; Hsu, V; Huang, SM; Nordmark, A; Zhang, L; Zhao, P; Zheng, JH, 2014
)
0.64
"46 ml/h/kg, and the elimination half-life time was 53."( Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.
Gattringer, KB; Jäger, W; Kraff, S; Thalhammer, F; Vossen, MG, 2014
)
0.4
" Probenecid increased the Cmax by 13% and the AUC by 21%."( Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Ariyawansa, J; Curtin, C; Devineni, D; Di Prospero, NA; Mamidi, RN; Murphy, J; Rothenberg, P; Stieltjes, H; Vaccaro, N; Wajs, E; Wang, SS; Weiner, S, 2015
)
1.59
"Organic anion transporters (OATs) are important in the renal secretion, and thus, the clearance, of many drugs; and their functional change can result in pharmacokinetic variability."( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017
)
0.46
"To measure the effect of probenecid, fasting and fed, on flucloxacillin pharmacokinetic and pharmacodynamic endpoints."( Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
Begg, EJ; Begg, R; Chambers, ST; Everts, RJ; Gardiner, SJ; Turnidge, J; Zhang, M, 2020
)
2.3
" Flucloxacillin pharmacokinetic and pharmacodynamic endpoints were compared."( Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
Begg, EJ; Begg, R; Chambers, ST; Everts, RJ; Gardiner, SJ; Turnidge, J; Zhang, M, 2020
)
2
" As an example of this pharmacodynamic improvement, the probability of target attainment of free concentrations above the minimum inhibitory concentration for Staphylococcus aureus (0."( Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
Begg, EJ; Begg, R; Chambers, ST; Everts, RJ; Gardiner, SJ; Turnidge, J; Zhang, M, 2020
)
2
"Probenecid increased flucloxacillin exposure, with predicted pharmacodynamic effects greater than pharmacokinetic effects because of the altered shape of the concentration-time curve."( Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
Begg, EJ; Begg, R; Chambers, ST; Everts, RJ; Gardiner, SJ; Turnidge, J; Zhang, M, 2020
)
3.44
" Using in vitro kinetic parameters for TFV and the OAT1 and OAT3 inhibitor probenecid, a bottom-up physiologically-based pharmacokinetic model was successfully developed for the first time that accurately describes the probenecid-TFV interaction."( Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Desta, Z; Gufford, BT; Liu, SN, 2020
)
2.23
"To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling."( Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz, H; Fernandez, É; Hanke, N; Lehr, T; Nock, V; Prasad, B; Stopfer, P; Taub, ME; Wang, T, 2020
)
1.02
" The objective of this study was to develop a population pharmacokinetic model for PDA and HVA to support biomarker qualification."( Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters.
Ahmad, A; Galetin, A; Jacobs, F; Kunze, A; Ogungbenro, K; Rostami-Hodjegan, A; Snoeys, J, 2021
)
0.62
" We developed a population pharmacokinetic model of free flucloxacillin concentrations within Monolix, and used Monte Carlo simulation to explore optimal dosing regimens to attain PK/PD targets proposed in the literature (free drug time above minimum inhibitory concentration)."( Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Chambers, ST; Drennan, PG; Everts, RJ; Gardiner, SJ; Green, JK; Kirkpatrick, CMJ; Metcalf, SCL; Zhang, M, 2021
)
0.84
" Standard pharmacokinetic measures and contemporary PK/PD targets were compared."( Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers.
Begg, EJ; Begg, R; Chambers, ST; Everts, RJ; Gardiner, SJ; Turnidge, J; Zhang, M, 2021
)
2.06
" The uricosuric agent probenecid inhibits tubular excretion of antibiotics and may be used as β-lactam pharmacokinetic enhancer (BLPKE), even though few data are currently available for this purpose."( Probenecid, an old β-lactams pharmacokinetic enhancer for a renewed use: A retrospective study.
Gallien, S; Habibi, A; Hulin, A; Huriez, P; Lepeule, R; Ourghanlian, C; Razazi, K; Vindrios, W, 2022
)
2.48

Compound-Compound Interactions

The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats. We sought to verify brain exposure of the systemically administered antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probeceid. The maximum-tolerated dose of this drug combination was pralatrexate 40 mg/m(2), and probesecid 140 mg/ m(2).

ExcerptReferenceRelevance
"5 g orally) in combination with 1 g of probenecid (instant therapy)."( Treatment of urogenital/rectal gonorrhoea in males and females with epicillin in combination with probenecid.
de Koning, GA; Michel, MF; Schuller, JL; Stolz, E, 1978
)
0.74
"11 registered thyphoid carriers were treated by cholecystectomy combined with amoxycillin + probenecid in our department."( Curing of typhoid carriers by cholecystectomy combined with amoxycillin plus probenecid treatment.
Békési, S; Münnich, D, 1979
)
0.71
" These involve a decrease in absorption when fluoroquinolones are given in combination with multivalent metal cations and an inhibition in the metabolism of methylxanthines by fluoroquinolones such as ciprofloxacin, enoxacin, and norfloxacin."( Drug interactions with fluoroquinolones.
Stein, GE, 1991
)
0.28
" The clinician should be aware of important drug-drug interactions prior to prescribing NSAIDs."( Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs).
Weinblatt, ME, 1989
)
0.28
"Ceftazidime pharmacokinetic values were studied in unweaned calves given the antibiotic alone or in combination with probenecid."( Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.72
" Since IAHQ has only modest activity against L1210 leukemia in mice, it was tested in combination with methotrexate (MTX), probenecid, or verapamil in an effort to enhance efficacy."( Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil.
Gale, GR; Hynes, JB; Smith, AB, 1986
)
0.68
" In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir."( The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H, 2002
)
0.31
"The pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin were investigated in goats given enrofloxacin alone or in combination with probenecid."( Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
Ahmad, AH; Malik, JK; Ramesh, S; Rao, GS; Sharma, LD; Tripathi, HC, 2002
)
0.72
" The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans."( A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006
)
0.78
"For patients with advanced solid tumors, the maximum-tolerated dose of this drug combination was pralatrexate 40 mg/m(2) and probenecid 140 mg/m(2)."( A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006
)
0.77
"The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats."( Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
Chida, M; Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2006
)
0.77
" The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process."( Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Fuse, E; Koepsell, H; Kusuhara, H; Maeda, K; Sugiyama, Y; Tahara, H, 2006
)
0.75
" Although kynurenic acid does not cross the BBB, its precursor, kynurenine, if combined with probenecid, crosses it readily."( Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.
Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Mihály, A; Németh, H; Toldi, J; Vécsei, L, 2007
)
0.85
" The present investigation tested the hypothesis of whether kynurenine in combination with systemically administered probenecid protects second-order trigeminal neurons against stimulation arriving via central processes of trigeminal ganglion cells."( Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid.
Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Németh, H; Toldi, J; Vécsei, L, 2007
)
0.75
" Probenecid plus oseltamivir 45 mg achieved all the pharmacokinetic parameters expected of oseltamivir alone, but combination with oseltamivir 30 mg and dose interval extension approaches did not."( Population pharmacokinetics of oseltamivir when coadministered with probenecid.
Boak, LM; Chanu, P; Gieschke, R; Jonsson, EN; Rayner, CR, 2008
)
1.49
" Healthy volunteers were randomized to a three-arm, open-label study and given 75 mg oral oseltamivir every 24 h (group 1), 75 mg oseltamivir every 48 h (q48h) combined with 500 mg probenecid four times a day (group 2), or 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3) for 15 days."( Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008
)
0.78
"Cimetidine is known to cause drug-drug interactions (DDIs) with organic cations in the kidney, and a previous clinical study showed that coadministration of cimetidine or probenecid with fexofenadine (FEX) decreased its renal clearance."( The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine.
Horita, S; Inoue, K; Kondo, T; Kusuhara, H; Maeda, K; Matsushima, S; Nakayama, H; Ohta, KY; Sugiyama, Y; Yuasa, H, 2009
)
0.55
" Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of L-kynurenine (L-KYN) combined with probenecid (PROB) or with 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC."( l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus.
Bohár, Z; Fülöp, F; Párdutz, A; Tajti, J; Toldi, J; Vámos, E; Varga, H; Vécsei, L, 2009
)
0.85
" On the basis of diet intervention, the observation group was treated with electroacupuncture at local points combined with blood-letting puncture and cupping, and the control group with oral administration of Probenecid."( [Observation on therapeutic effect of electroacupuncture plus blood-letting puncture and cupping combined with diet intervention for treatment of acute gouty arthritis].
Gao, Y; Li, W; Liu, J; Qu, XD; Wang, S; Zhao, QW; Zhu, LW, 2009
)
0.54
" Drug-drug interactions may occur at a pharmacokinetic or pharmacodynamic level."( [Drug-drug interactions and nephrotoxicity].
Czock, D; Keller, F, 2011
)
0.37
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" We used a panel of stably and transiently transfected cell lines to elucidate the carrier-mediated transport processes that are involved in linagliptin disposition in vivo and to assess the potential for drug-drug interactions (DDIs)."( Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Ebner, T; Ishiguro, N; Kishimoto, W; Schaefer, O; Shimizu, H, 2013
)
0.39
"This case study illustrates the difficulty in predicting clinically relevant drug-drug interactions for UGT substrates based only on the fraction metabolized by glucuronidation."( In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics.
Aceves Baldó, P; Anzures-Cabrera, J; Bentley, D, 2013
)
0.61
" Drug-drug interactions (DDIs) via inhibition of renal organic anion (OAT) and organic cation (OCT) transporters have been observed in the clinic."( Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.
Corrigan, B; El-Kattan, A; Feng, B; Hurst, S; Lockwood, P; Lu, Y; Rotter, CJ; Varma, MV, 2013
)
0.39
"We established a novel technique for quantifying [Na+]i in cultured neonatal rat cardiomyocytes attached to a 96-well plate using a microplate reader in combination with SBFI and probenecid."( A technique for quantifying intracellular free sodium ion using a microplate reader in combination with sodium-binding benzofuran isophthalate and probenecid in cultured neonatal rat cardiomyocytes.
Date, T; Hongo, K; Ito, K; Katoh, D; Kawai, M; Kayama, Y; Komukai, K; Yoshimura, M; Yoshino, T, 2013
)
0.78
"25 when administered in combination with probenecid."( Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Chen, J; Hanna, I; Koo, P; Majumdar, T; Mendonza, A; Meyers, D; Neelakantham, S; Rebello, S; Sunkara, G; Zhu, B, 2016
)
0.92
" Preclinical studies of GTx-024 supported the evaluation of several potential drug-drug interactions in a clinical setting."( Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.
Coss, CC; Dalton, JT; Jones, A, 2016
)
0.64
" Twelve healthy men were administered a single oral dose of ritobegron (20 mg) alone or in combination with probenecid 2 hours before administration of ritobegron."( Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men.
Abe, Y; Endo, T; Furihata, T; Kanazawa, T; Kobayashi, M; Nakano, Y, 2016
)
0.86
" This mechanistic static approach was further applied to quantitatively predict renal drug-drug interactions (AFE ∼1."( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017
)
0.46
"A PBPK modelling approach was used to predict organic anion transporter (OAT) mediated drug-drug interactions involving S44121, a substrate and an inhibitor of OAT1 and OAT3."( Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling.
Ball, K; Chenel, M; Denizot, C; Jamier, T; Mallier, A; Parmentier, Y, 2017
)
0.46
" We sought to verify brain exposure of the systemically administered antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probenecid, and identify adverse effects of this drug combination after severe TBI in children."( Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children.
Au, AK; Bayır, H; Bell, MJ; Clark, RSB; Empey, PE; Horvat, CM; Kochanek, PM; Nolin, TD; Poloyac, SM; Rosario, BL; Wisniewski, SR, 2017
)
0.88
"To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling."( Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz, H; Fernandez, É; Hanke, N; Lehr, T; Nock, V; Prasad, B; Stopfer, P; Taub, ME; Wang, T, 2020
)
1.02
" Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular mechanisms of renal excretion and potential drug-drug interactions (DDIs) remain unclear."( OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro.
Dong, S; Fan, H; Huo, X; Li, C; Li, W; Liu, J; Peng, Y; Yang, F; Yuan, Y; Zhang, A; Zhang, N; Zheng, J; Zhou, S, 2023
)
0.91

Bioavailability

The pharmacokinetics and bioavailability of probenecid given IV and orally at the dosage level of 10 mg/kg of body weight to mares were investigated. The volume of distribution at steady-state and systemicBioavailability of AZT were not significantly altered by proben Cecid.

ExcerptReferenceRelevance
" These findings suggest that 3g amoxycillin plus 1g probenecid provide better bioavailability than 3g amoxycillin alone."( Clinical pharmacological studies of amoxycillin: effect of probenecid.
Barbhaiya, R; Thin, RN; Turner, P; Wadsworth, J, 1979
)
0.75
" Ampicillin seemed to be poorly absorbed from the gastrointestinal tract of fowls."( Effects of probenecid on blood levels and tissue distribution of ampicillin in fowls and turkeys.
Fridman, J; Meshorer, A; Neumann, J; Singer, N; Ziv, E; Ziv, G,
)
0.52
" Lower peak levels but comparable bioavailability were obtained after intramuscular administration."( Pharmacokinetic studies with mecillinam and pivmecillinam.
Nielsen, B; Roholt, K, 1975
)
0.25
" The volume of distribution at steady-state and systemic bioavailability of AZT were not significantly altered by probenecid."( Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys.
Finco, TS; Gallo, JM; Mehta, M; Qian, MX; Viswanathan, CT, 1991
)
0.73
" Pretreatment with probenecid produced significant increases in absolute peak and plasma diuretic concentrations, t1/2 and mean residence time while decreasing steady-state volume of distribution, total clearance, renal clearance and fraction of unchanged drug excreted without affecting the bioavailability of piretanide."( Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
Dixey, JJ; Lant, AF; McNabb, WR; Noormohamed, FH, 1990
)
0.82
"1 min and the estimated bioavailability after intramuscular administration was 76."( Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.28
" The absolute bioavailability of the administered tablet was practically 100%."( Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Dell, D; Lücker, PW; Partos, C; Portmann, R; Suter, K; Weidekamm, E, 1987
)
0.27
" Bioavailability of probenecid was 117 and 102% for 2 mares after a single intragastric dose, compared with a single IV dose."( Probenecid infusion in mares: effect on para-aminohippuric acid clearance.
Brown, MP; Gronwall, R, 1988
)
2.04
" bioavailability of two injectable oily suspensions of the drug was 44%; both formulations failed to produce serum drug concentrations of potential clinical significance after administration at 20 mg/kg."( Clinical pharmacokinetics of flumequine in calves.
Bor, A; Kurtz, B; Soback, S; Ziv, G, 1986
)
0.27
"The pharmacokinetics and bioavailability of probenecid given IV and orally at the dosage level of 10 mg/kg of body weight to mares were investigated."( Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
Ashcraft, SM; Donecker, JM; Sams, RA, 1986
)
0.86
" injection, probenecid and cefotaxime were well tolerated and cefotaxime was well absorbed (101 +/- 45%)."( Effect of probenecid on the pharmacokinetics of cefotaxime in sheep.
Bourne, DW; Cao, GR; English, PB; Filippich, LJ; Guerrini, VH, 1985
)
1.05
" The rate of absorption of isofezolac was not affected."( Effect of probenecid on isofezolac kinetics.
Bannier, A; Brazier, JL; Chauliac, F; Comet, F; Soubeyrand, J, 1985
)
0.67
" Some animals received 200 mg/kg probenecid intraperitoneally and this reduced the rate of absorption from injectates into the corpus striatum to 65."( Organic acid transport to the blood from the corpus striatum, the thalamus and the cerebellum of the rat.
Andén, NE; Bárány, E; Grabowska-Andén, M; Magnusson, A, 1984
)
0.55
" The absorption rate for benzylpenicillin from the mammary gland was reduced by probenecid, as measured by the ratio of benzylpenicillin to urea absorption half-life, which was increased by 40-50% in the presence of probenecid."( Active transport of benzylpenicillin across the blood-milk barrier.
Frey, HH; Merck, CC; Nielsen, P; Rasmussen, F; Schadewinkel-Scherkl, AM, 1993
)
0.51
"5 mg/kg of body weight to ponies and horses, and was highly bioavailable (F = 41."( Pharmacokinetics of bacampicillin in equids.
McKellar, QA; Sarasola, P, 1995
)
0.29
" Cidofovir and adefovir are dianionic at physiological pH and have low oral bioavailability in animals and humans."( Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy, KC, 1999
)
0.3
" The mean (+/- SD) bioavailability of R-clinafloxacin was 87."( Pharmacokinetics of clinafloxacin enantiomers in humans.
Brodfuehrer, JI; Guttendorf, RJ; Humphrey, GH; Randinitis, EJ; Shapiro, MA, 1999
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" MRP type efflux pumps may limit the bioavailability of EGCG."( Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
Hong, J; Lambert, JD; Lee, SH; Sinko, PJ; Yang, CS, 2003
)
0.32
"To investigate whether P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs), which limit the bioavailability of HIV protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs), modulate the anti-HIV activity of NRTIs, non-NRTIs and PIs in vitro."( ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Becher, F; Benech, H; Clayette, P; Dereuddre-Bosquet, N; Dormont, D; Garrigues, A; Grassi, J; Jorajuria, S; Mabondzo, A; Martin, S; Orlowski, S; Porcheray, F, 2004
)
0.32
"This study suggests that verapamil increases fexofenadine exposure probably because of an increase in bioavailability through P-glycoprotein inhibition and that probenecid slightly increases the area under the plasma concentration-time curve of fexofenadine as a result of a pronounced reduction in renal clearance."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.75
"It is known that secretory transport limits the oral bioavailability of certain drugs."( Characterization of secretory intestinal transport of phenolsulfonphthalein.
Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Miyazaki, K; Shimamoto, S; Sugawara, M, 2005
)
0.33
" The bioavailability of ampicillin, taken as the area under the serum curve, obtained with pivampicillin at a 250-mg ampicillin dose level was superior to that obtained with a 500-mg dose of ampicillin."( Clinical pharmacology of pivampicillin.
Kristensen, E; Nielsen, B; Roholt, K, 1974
)
0.25
" The efflux of Mrp2, not P-gp, in the intestinal of the rats may be one of the reasons that lead to the low oral bioavailability of scutellarin."( Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
Cao, F; Guo, J; Ping, Q; Zhang, H, 2008
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The compound was well absorbed and exhibited approximately linear pharmacokinetics in the oral dose range of 100 to 1000 mg in human."( Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).
Adams, WJ; Balogh, LM; Brayman, TG; Cox, SR; Kumar, V; Lai, Y; Sampson, KE; Stevens, JC, 2010
)
0.36
" The P-gp efflux and CYP3A4 metabolism were involved in the poor intestinal absorption and low bioavailability of limonin."( [Transport of limonin in rat intestine in situ and Caco-2 cells in vitro].
He, L; Ke, X; Tian, JL; Zhang, XY, 2012
)
0.38
" Its oral bioavailability is low and its intestinal absorption mechanism is not clear."( Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers.
Li, X; Lu, Y; Yin, Z; Yu, Y; Zhao, X, 2013
)
0.39
" Furthermore, it reinforces the notion that the physical and chemical properties that determine a compound's bioavailability in vivo will be critical in determining the efficacy of Kir channel inhibitors as insecticides."( Discovery and characterization of a potent and selective inhibitor of Aedes aegypti inward rectifier potassium channels.
Bollinger, SF; Bollinger, SR; Days, E; Denton, JS; Engers, DW; Hopkins, C; Konkel, LC; Lovell, KM; Piermarini, PM; Raphemot, R; Rouhier, MF; Swale, DR; Weaver, CD, 2014
)
0.4
" Comparing the TFG absorption rate in different intestinal segments, data showed that the small intestine absorption was significantly higher than that of the colon ([Formula: see text])."( Absorption Properties of Luteolin and Apigenin in Genkwa Flos Using In Situ Single-Pass Intestinal Perfusion System in the Rat.
He, X; Jiang, CP; Song, ZJ; Zhang, CF, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Allopurinol is more frequently used than uricosuric agents such as probenecid, and toxicity may be largely avoided by tailoring dosage schedules according to renal function. Administration of 500 mg probenacid every 6 hr prior to and during AZT dosing resulted in an increase in the average AUCAZT from 89 micrograms.

ExcerptRelevanceReference
" Hence probenecid should not be used to reduce rifampicin dosage in antituberculosis therapy."( Probenecid and rifampicin serum levels.
Allan, GW; Fallon, RJ; Lees, AW; Smith, J; Tyrrell, WF, 1975
)
2.15
"In a systematic study of dose-response relationship 883 patients with uncomplicated gonorrhoea were given single oral doses of 400, 800 or 1600 mg bacampicillin, with 1 g probenecid."( A dose response study with bacampicillin in uncomplicated gonorrhoea.
Bengtsson, S; Eriksson, G; Kallings, LO; Sandström, E; Wallin, J; Wallmark, G, 1979
)
0.45
" This article attempts to critically review these studies under seven different sections: furosemide pharmacokinetics in normal volunteers, furosemide pharmacokinetics in patients with decreased renal function, furosemide pharmacokinetics in patients with congestive heart failure, furosemide metabolism and assay methods, furosemide bioavailability, dose-response relationships, and the role of inhibitors and mediators on furosemide effects."( Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
Benet, LZ, 1979
)
0.26
" After dosing cinoxacin alone, steady-state serum levels were approached in 1 h and were maintained for an additional 2 h with a reduced infusion rate."( Influence of probenecid on serum levels and urinary excretion of cinoxacin.
Madsen, PO; Rodriguez, N; Welling, PG, 1979
)
0.63
" In a dosage of 100 and 300 mg/day benzbromaron proved to be a much more potent uricosuricum."( [The uricosuric effect of benzbromaron and probenecid under fasting conditions (author's transl)].
Kleinschmidt, A; Schräpler, P; Schulz, E, 1978
)
0.52
" By prolonging the duration of these high cefamandole levels, probenecid should permit the treatment of more serious clinical infections, including those due to relatively resistant organisms, or permit a reduction in either the dosage of cefamandole or the frequency of administration."( Effect of probenecid on the blood levels and urinary excretion of cefamandole.
Black, HR; Brier, GL; Griffith, RS; Wolny, JD, 1977
)
0.9
" Biliary excretion of radioactivity after 14C-probenecid administration was found to be saturated at a dosage of 100 mg X kg-1."( Probenecid-induced effects on bile flow and biliary excretion of 3H-ouabain.
Damm, KH; Erttmann, RR, 1976
)
1.96
" Its cure rate has been relative, and because cure rates are not as good as one would wish, an additional increase in dosage has been advised."( Treatment of uncomplicated gonorrhea with Polycillin-PRB.
Hall, SW; Hartford, TJ; Kleris, GS, 1976
)
0.26
" Controls over a 15-weeks period showed that this dosage did prevent the development of syphilitic orchitis and reactivity to the quantitative FTA-ABS-test."( [The effect of pivampicillin and probenecid on experimental syphilis in rabbits].
Petzoldt, D, 1975
)
0.54
" At 110 min after dosing, subjects took a slow, full inspiration with a 30 s breath-hold, and at 150 min after dosing the subjects performed one single forced expiration."( The effect of respiratory manoeuvres and pharmacological agents on the pharmacokinetics of nedocromil sodium after inhalation.
Holgate, ST; Honeywell, RG; Renwick, AG; Singh, S; Summers, QA, 1992
)
0.28
" Comparison of dose-response curves for shift and block imposed by the inhibitor, indicate two different sites within the channel which interact with the ligand."( Identification and modulation of a voltage-dependent anion channel in the plasma membrane of guard cells by high-affinity ligands.
al-Awqati, Q; Hedrich, R; Landry, DW; Marten, I; Redhead, C; Zeilinger, C, 1992
)
0.28
" The ampicillin concentrations observed suggest that the dosing interval for horses may be increased from between six and eight hours to 12 hours when probenecid is administered in conjunction with the ampicillin."( Effect of probenecid on disposition kinetics of ampicillin in horses.
McKellar, QA; Sarasola, P, 1992
)
0.88
" The Cmax was 14 micrograms/ml with a dosage of 250 mg, 31 micrograms/ml with 500 mg, 70 micrograms/ml with 1,000 mg and 120 micrograms/ml with 1,500 mg."( Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.
Hekster, YA; Van Ewijk-Beneken Kolmer, EW; Vree, TB; Wuis, EW, 1992
)
0.55
" The concentration of TBZ in blood at 1 or 5 hr after dosing was lower in mice pretreated with microsomal monooxygenase system inducers and was higher in those pretreated with the inhibitors, than in those given TBZ alone."( Acute renal toxicity of thiabendazole (TBZ) in ICR mice.
Fujitani, T; Tada, Y; Yoneyama, M, 1992
)
0.28
" Because loracarbef is eliminated primarily by the kidney, dosage must be reduced in patients with moderate-to-severe renal insufficiency."( Pharmacokinetic profile of loracarbef.
DeSante, KA; Zeckel, ML, 1992
)
0.28
" Urinary recovery in an 8-hour period was not significantly different between CF subjects and controls nor was the percentage of dose recovered in the urine at each dosage level."( Probenecid pharmacokinetics in cystic fibrosis.
de Groot, R; Ramsey, B; Smith, A; Weber, A; Williams-Warren, J, 1991
)
1.72
" This could be completely blocked by combination dosing with allopurinol, an inhibitor of xanthine oxidase."( Hyperuricemia induced by the uricosuric drug probenecid in rats.
Shinosaki, T; Yonetani, Y, 1991
)
0.54
"01); these differences caused by fluid replacement did not however occur after oral dosing of piretanide (181 +/- 12 vs 167 +/- 14 mmol 6 h-1)."( Analysis of the natriuretic action of a loop diuretic, piretanide, in man.
Lant, AF; Noormohamed, FH, 1991
)
0.28
" Administration of 500 mg probenecid every 6 hr prior to and during AZT dosing resulted in an increase in the average AUCAZT from 89 micrograms."( Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers.
Elmquist, WF; Hedaya, MA; Sawchuk, RJ, 1990
)
2.02
" dosing in the nonhydrated state where changes in drug excretion after probenecid (2."( Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
Dixey, JJ; Lant, AF; McNabb, WR; Noormohamed, FH, 1990
)
0.72
" Nevertheless, in individuals who cannot tolerate a high single dose of amoxycillin, there is need for an alternative dosage regimen."( Pharmacokinetic comparison of two models of endocarditis prophylaxis with amoxycillin.
Höglund, P; Paulsen, O; Schalén, C, 1989
)
0.28
" Ceftazidime was administered IV to 9 calves at a dosage of 10 mg/kg of body weight and IM (10 mg/kg) to 8 calves, to 7 calves (10 mg/kg plus probenecid [40 mg/kg]), and to 9 calves (10 mg/kg plus probenecid [80 mg/kg])."( Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves.
Soback, S; Ziv, G, 1989
)
0.72
" In rats, continuous infusion of ANF resulted in a bell-shaped dose-response relationship."( The character of the atrial natriuretic response: pressure and volume effects.
Blaine, EH; Heinel, LA; Marsh, EA; Schorn, TW; Whinnery, MA, 1986
)
0.27
" At a dosage of 200 mg/kg, probenecid accumulated in the serum from the 1st to the 5th dose."( Probenecid infusion in mares: effect on para-aminohippuric acid clearance.
Brown, MP; Gronwall, R, 1988
)
2.01
" and oral drug administration were used to calculate practical dosage recommendations."( Clinical pharmacokinetics of flumequine in calves.
Bor, A; Kurtz, B; Soback, S; Ziv, G, 1986
)
0.27
" Urinary dose-response curves showed torasemide to be five times as potent as furosemide."( Clinical pharmacology of torasemide, a new loop diuretic.
Anderson, SA; Brater, DC; Leinfelder, J, 1987
)
0.27
"The pharmacokinetics and bioavailability of probenecid given IV and orally at the dosage level of 10 mg/kg of body weight to mares were investigated."( Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
Ashcraft, SM; Donecker, JM; Sams, RA, 1986
)
0.86
" The serum AUC for total radioactivity and for intact drug after intramuscular dosing were similar to those obtained after intravenous dosing."( Pharmacokinetics of Sch 34343 in rats and dogs.
Chung, M; D'Souza, R; Kim, H; Korduba, C; Lim, J; Lin, C; Loebenberg, D; Moss, E; Oden, E; Veals, J, 1985
)
0.27
"A liquid chromatographic (LC) method for the determination of colchicine in pharmaceutical dosage forms and the bulk drug was evaluated in an interlaboratory study which included 13 participating laboratories."( Liquid chromatographic determination of colchicine in pharmaceuticals: collaborative study.
Thompson, RD,
)
0.13
" Maximal accumulation is reached 2 h after IP administration at a dosage of 150 mg/kg body weight."( The effects of probenecid on cyclic adenosine 3',5'-monophosphate levels in cerebrospinal fluid and on brain phosphodiesterase activity in the rat.
Clarenbach, P; Cramer, H; Hammers, R; Horstmann, R, 1983
)
0.62
" The aim of the present study was to extend these observations, by examining the dose-response and to compare the uricosuric effect of azapropazone with that of probenecid."( The uricosuric action of azapropazone: dose-response and comparison with probenecid.
Higgens, CS; Scott, JT, 1984
)
0.7
" The shapes of the dose-response curves for inhibition of the organic cation and organic anion transport are different, and the inhibition is competitive in each case."( Mechanisms for the renal secretion of cisplatin.
Herbert, BH; Nelson, JA; Santos, G, 1984
)
0.27
" Compared with probenecid, thimerosal and mercaptide V yielded dose-response curves of steeper slope and higher maximal effect."( Effects of analogs of salicylate on p-aminohippurate uptake into basal-lateral membranous vesicles.
Bildstein, C; Liu, D; Mamelok, RD; Tse, SS, 1984
)
0.62
" The dose-response curves for three different inhibitors were identical for the OH- and Cl- gradient-stimulated modes of urate uptake."( Urate transport via anion exchange in dog renal microvillus membrane vesicles.
Aronson, PS; Kahn, AM, 1983
)
0.27
"Dyphylline is a methylxanthine bronchodilator with such a short a biologic t 1/2 that development of practical dosing regimens has been difficult."( Effect of probenecid on dyphylline elimination.
Jarboe, CH; May, DC, 1983
)
0.67
" In the dosage range under study, the probenecid homologues show linear dose-response relationships."( [Inhibition of the renal excretion of PAH by probenecid homologs].
Appenroth, D; Bräunlich, H, 1983
)
0.8
" However, analysis of the dose-response curves between treatments I and II showed that sodium excretion was better correlated with bumetanide urinary excretion rate than with plasma concentration."( Determinants of bumetanide response in the dog: effect of probenecid.
Lau, HS; Smith, DE, 1983
)
0.51
" The serum half life of ceftizoxime after dosing of probenecid and ceftizoxime in combination was about twice longer in rabbits than and almost the same in dogs as that after dosing of ceftizoxime alone."( [Mechanism of renal excretion of ceftizoxime in rabbits and dogs (author's transl)].
Murakawa, T; Nakamoto, S; Nishida, M, 1980
)
0.51
" Dosage adjustment for various stages of renal impairment are proposed based on the observed relationship between Cltot and Clcr."( Overview of acyclovir pharmacokinetic disposition in adults and children.
Blum, MR; de Miranda, P; Liao, SH, 1982
)
0.26
" It has been presumed that this paradox is accounted for by differences in rate of delivery of furosemide to the active site such that after an oral dose, or after pretreatment with probenecid, amounts of drug are for longer periods of time at the "steep" portion of the dose-response curve."( The time course of delivery of furosemide into urine: an independent determinant of overall response.
Brater, DC; Day, B; Kaojarern, S, 1982
)
0.46
" A further three volunteers were dosed intravenously with a 5 g bolus of non-radiolabelled ticarcillin in a cross-over study with and without predosing with probenecid."( Pharmacokinetics of ticarcillin in man.
Davies, BE; Humphrey, MJ; Langley, PF; Lees, L; Legg, B; Wadds, GA, 1982
)
0.46
" In contrast, there seemed to be a correlation between dopamine turnover and optimum dosage of l-DOPA."( [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
Mendlewicz, J; Noel, G; Vanderheyden, JE,
)
0.49
" Muscle relaxants do not cause measurable muscle relaxation following usual oral dosage regimens."( Effects of exercise performance on drugs used in musculoskeletal disorders.
Day, RO, 1981
)
0.26
" Salicylate (an anion) and quinine (a cation), in dosage which inhibited allantoin uptake, also inhibit the uptake of the para-aminohippuric acid (an anion) and tetraethylammonium bromide (a cation)."( Renal handling of [14C]allantoin in the rabbit.
Roch-Ramel, F; Schäli, C, 1980
)
0.26
" However, analysis of the time course of natriuresis showed a pattern similar to that of the urinary furosemide excretion rate, whereas the plasma concentration was poorly correlated over the entire dose-response curve."( Preliminary evaluation of furosemide-probenecid interaction in humans.
Benet, LZ; Brater, DC; Gee, WL; Lin, ET; Smith, DE, 1980
)
0.53
" A Hill plot of the dose-response curve yielding a slope of unity suggested one furosemide molecule combines with one chloride transport site."( Mode of action of furosemide on the chloride-dependent short-circuit current across the ciliary body epithelium of toad eyes.
Horiuchi, K; Itoi, K; Saito, Y; Watanabe, T, 1980
)
0.26
"We dosed eight normal volunteers with single doses of probenecid alone and with aspirin or ibuprofen."( Effect of ibuprofen or aspirin on probenecid-induced uricosuria.
Brooks, CD; Ulrich, JE, 1980
)
0.79
"5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)."( (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Cundy, K; Drew, WL; Fisher, PE; Flaherty, J; Glutzer, E; Hannigan, J; James, C; Lalezari, JP; Martin, JC; Miner, D, 1995
)
0.58
" Allopurinol is more frequently used than uricosuric agents such as probenecid, and toxicity may be largely avoided by tailoring dosage schedules according to renal function."( Risks and benefits of drugs used in the management and prevention of gout.
Conaghan, PG; Day, RO, 1994
)
0.52
" Studies with [35S]-PAP-GSH at 40 mumol kg-1 showed selective retention of radioactivity in the kidney, relative to other organs 24 h after dosing and that some radioactivity was covalently bound to renal proteins."( Nephrotoxicity of 4-amino-3-S-glutathionylphenol and its modulation by metabolism or transport inhibitors.
Foster, JR; Fowler, LM; Lock, EA, 1994
)
0.29
"Male Sprague-Dawley rats had their bile ducts cannulated and were dosed with [3H]taxol (2 mg/kg, 68-77 microCi/mg) as a continuous intravenous infusion for 6 hr so that the plasma concentrations, tissue distribution, metabolism, and biliary secretion of taxol could be studied."( Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
Collins, JM; Egorin, MJ; Erkmen, K; Jamis-Dow, CA; Klecker, RW; Parker, RJ; Stevens, R,
)
0.45
"Reduction in the dosage of dicloxacillin from 500 mg to 250 mg 3 times a day would mean lowering of costs and less side-effects in orthopaedic infections."( Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid.
Hansen, BA; Jensen, P; Krogsgaard, MR; Slotsbjerg, T, 1994
)
0.74
" In this study we have examined the distribution and covalent binding of radiolabel from 4-[ring 3H]-aminophenol in the plasma, kidney and liver of rats 24 h after dosing and related these findings to the extent of nephrotoxicity."( Effect of ascorbic acid, acivicin and probenecid on the nephrotoxicity of 4-aminophenol in the Fischer 344 rat.
Foster, JR; Fowler, LM; Lock, EA, 1993
)
0.56
" The major portion of both enantiomers was excreted by 6 h after dosing and 77-78% of the dose was recovered within 48 h, principally as the unchanged drug."( Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey.
Higaki, K; Kawahara, S; Nakano, M, 1993
)
0.49
" Prolonged probenecid therapy before administration of a cephalosporin did not seem to be as relevant as the probenecid dosage in determining the magnitude of the interaction."( Cephalosporin-probenecid drug interactions.
Brown, GR, 1993
)
1.04
" Considering the short half-life of zalcitabine (1-3 hours) relative to its dosing schedule, the pharmacokinetic changes observed in this study are not expected to result in significant accumulation during chronic dosing."( The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
Massarella, JW; Min, B; Nazareno, LA; Passe, S, 1996
)
0.65
" Although well tolerated in this single-dose study, patients taking this combination should be monitored closely for signs of toxicity and dosage reduction should be considered if warranted."( The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
Massarella, JW; Min, B; Nazareno, LA; Passe, S, 1996
)
0.65
" The prolonged elimination phase observed in monkeys is consistent with the long intracellular half-life of phosphorylated cidofovir in vitro and supports infrequent dosing of the drug for antiviral therapy."( Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.
Cundy, KC; Hitchcock, MJ; Lee, WA; Li, ZH, 1996
)
0.29
" In addition, four treatment modifications were indicated to reduce the incidence of cidofovir-related nephrotoxicity: (a) dose reduction or interruption for changes in renal function; (b) concomitant administration of probenecid; (c) administration of 1 L of normal saline 1 h before infusion of cidofovir; and (d) extension of the dosing interval."( Cidofovir: a new therapy for cytomegalovirus retinitis.
Lalezari, JP, 1997
)
0.48
"Elimination of drug molecules via tubular secretion is an important pharmacokinetic parameter especially for oral dosage forms where an extremely short half-life would prevent their application."( Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion.
Ehlert, C; Seydel, JK; Strunz, H; Visser, K; Wiese, M, 1998
)
0.3
" Measurements included serial blood and urine samples during the dosing intervals at steady state."( Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Casserella, S; Cimoch, PJ; Griffy, KG; Jung, D; Lavelle, J; Pollard, R; Tarnowski, TL; Wong, R, 1998
)
0.52
" A pretreatment regimen consisting of prednisone, H1 and H2 blockers was administered before the dosing of probenecid in order for the patient to continue with the antiviral therapy."( Probenecid hypersensitivity in AIDS: a case report.
Engler, RJ; Katial, RK; Myers, KW, 1998
)
1.96
" This process allowed serum concentrations to be above the minimal inhibitory concentrations (MIC) for the most likely skin pathogens (Staphylococcus aureus, beta-hemolytic streptococci) at the end of the dosing interval."( Once-daily cefazolin and probenecid for skin and soft tissue infections.
Cox, VC; Zed, PJ, 2004
)
0.63
" The results indicate that berberine displays a linear pharmacokinetic phenomenon in the dosage range from 10 to 20 mg kg(-1), since a proportional increase in the area under the concentration-time curve (AUC) of berberine was observed in this dosage range."( Hepatobiliary excretion of berberine.
Tsai, PL; Tsai, TH, 2004
)
0.32
" Dose-response curves for transport and the ratio of dye concentration in the secreted fluid to that in the bathing medium (S/M) were determined for Texas Red as well as for P-gp substrates (rhodamine 123, daunorubicin), the organic anion fluorescein and the organic cation quinacrine."( Transepithelial transport of fluorescent p-glycoprotein and MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted fluid droplets.
Leader, JP; O'Donnell, MJ, 2005
)
0.33
" Competitive, noncompetitive and uncompetitive inhibition mechanisms were incorporated into the GHB-MCT substrate interaction model for inhibitor dosing either pre-, concurrent or post-GHB administration."( Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.
Bhattacharya, I; Boje, KM, 2006
)
0.33
" This study aimed to establish its mechanism of action and to construct a dose-response curve for the effect of allopurinol."( High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
Belch, JJ; Carr, E; Davies, J; George, J; Struthers, A, 2006
)
0.33
"For the first time, we have shown that a steep dose-response relationship exists between allopurinol and its effect on endothelial function."( High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
Belch, JJ; Carr, E; Davies, J; George, J; Struthers, A, 2006
)
0.33
"4% in rats, with non-linear pharmacokinetics when its dosage increased."( Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Liu, PQ; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
0.34
" Venous blood samples were collected predose (at 0 hours) and 1, 2, 3, 4, 6, 8, 10 and 12 hours after dosage for determination of oxypurinol and/or probenecid concentrations."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
0.78
" In addition, increased dosing requirements may affect compliance and attainment of optimal oseltamivir exposure, potentially facilitating the emergence of viral strains with reduced susceptibility to oseltamivir."( Population pharmacokinetics of oseltamivir when coadministered with probenecid.
Boak, LM; Chanu, P; Gieschke, R; Jonsson, EN; Rayner, CR, 2008
)
0.58
" In the event of an influenza pandemic, oseltamivir supplies may be limited; thus, alternative dosing strategies for oseltamivir prophylaxis should be explored."( Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008
)
0.59
"Three common dosing regimens of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of Parkinson's disease (PD) were compared in C57BL/6 mice on behavior, striatal and extra-striatal neurotransmission, and brain cytokines, to clarify the differences between regimens on these variables."( Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
Luchtman, DW; Shao, D; Song, C, 2009
)
0.35
" In the topical dosing study, a significant decline in BAPSG delivery was observed in the iris-ciliary body but no significant changes were observed in other tissues of the anterior segment of the eye including tears."( Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.
Ayalasomayajula, SP; DeRuiter, J; Kompella, UB; Sunkara, G, 2010
)
1.8
" Co-administration of PRB with MZR appears to be effective in prolonging the biological half-life of MZR and enhancing its effect in patients with nephrotic syndrome, although further studies will be required to determine the optimal dosage of PRB and renoprotective effects."( Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome.
Hara, Y; Hashimoto, Y; Hosoya, T; Ito, H; Miyazaki, Y; Okonogi, H; Utsunomiya, Y, 2010
)
0.75
" All doses except the 250 mg daily dose were divided and dosing was twice daily."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
0.6
" Model predictions showed a relationship between plasma oxypurinol and urate concentrations and failure to reach target oxypurinol concentrations using suggested allopurinol dosing guidelines."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
0.38
" The exploration of the intestinal absorption mechanism is crucial to the design of dosage form and clinical use of limonin."( [Transport of limonin in rat intestine in situ and Caco-2 cells in vitro].
He, L; Ke, X; Tian, JL; Zhang, XY, 2012
)
0.38
" Allopurinol can be used for the prophylactic management of chronic hyperuricemia in patients with CKD, but the recommended decreased dosage may limit efficacy and serious hypersensitivity reactions may preclude its use."( Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Curiel, RV; Guzman, NJ, 2012
)
0.38
" This relationship allows for the prediction of systemic cidofovir exposure in individual patients and may be utilized to evaluate exposure-response relationships to optimize the cidofovir dosing regimen for BKV infection."( Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection.
Gao, Y; Momper, JD; Randhawa, PS; Schonder, KS; Shapiro, R; Venkataramanan, R; Zhao, Y, 2013
)
0.39
" Further trials have to be done to determine the right dosage of cidofovir in patients undergoing CVVH to avoid toxic accumulation of the drug."( Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.
Gattringer, KB; Jäger, W; Kraff, S; Thalhammer, F; Vossen, MG, 2014
)
0.4
" Studies have identified the safe and effective dosing strategies for 'old' drugs such as allopurinol and colchicine."( Advances in pharmacotherapy for the treatment of gout.
Dalbeth, N; Robinson, PC, 2015
)
0.42
" The dosage adjustment could result in increases in the plasma AUC0-∞ of tanshinol of about 100-fold."( Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions.
Dong, J; Du, F; Jia, W; Jiang, R; Li, C; Li, L; Liu, X; Olaleye, OE; Wang, F; Xu, F; Yang, J, 2015
)
0.42
"The Ki values for probenecid inhibition of 2ME2 glucuronide formation, when compared to maximum probenecid plasma concentrations anticipated clinically, indicate that probenecid co-administration has the potential to augment systemic plasma levels of 2ME2 after oral dosage in humans."( Inhibition of 2-methoxyestradiol glucuronidation by probenecid.
Castellot, J; Greenblatt, DJ; Matin, B; Qian, Y; Sherbini, A; Zhao, Y, 2015
)
1
" The aim of this study was to determine the effect of dosing time on the pharmacokinetics and brain distribution of morphine."( Diurnal variation in the pharmacokinetics and brain distribution of morphine and its major metabolite.
de Lange, ECM; Hartman, R; Kervezee, L; Meijer, JH; van den Berg, DJ, 2017
)
0.46
" His uric acid was 11 mg/dL despite maximal dosing of febuxostat."( Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Case, R; Jester, G; Wentworth, B, 2018
)
0.76
" The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended."( Gout - An update of aetiology, genetics, co-morbidities and management.
Robinson, PC, 2018
)
0.48
" The aims of this study were to develop a population PK model of free flucloxacillin when administered orally with probenecid, and to identify optimal dosing regimens for this combination."( Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Chambers, ST; Drennan, PG; Everts, RJ; Gardiner, SJ; Green, JK; Kirkpatrick, CMJ; Metcalf, SCL; Zhang, M, 2021
)
1.05
" We developed a population pharmacokinetic model of free flucloxacillin concentrations within Monolix, and used Monte Carlo simulation to explore optimal dosing regimens to attain PK/PD targets proposed in the literature (free drug time above minimum inhibitory concentration)."( Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Chambers, ST; Drennan, PG; Everts, RJ; Gardiner, SJ; Green, JK; Kirkpatrick, CMJ; Metcalf, SCL; Zhang, M, 2021
)
0.84
" Predicted PK/PD target attainment was suboptimal with standard dosing regimens with flucloxacillin alone, but substantially improved in the presence of probenecid."( Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Chambers, ST; Drennan, PG; Everts, RJ; Gardiner, SJ; Green, JK; Kirkpatrick, CMJ; Metcalf, SCL; Zhang, M, 2021
)
1.04
" Patients with higher FFM and eGFR may require the addition of probenecid and 6-hourly dosing to achieve PK/PD targets."( Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Chambers, ST; Drennan, PG; Everts, RJ; Gardiner, SJ; Green, JK; Kirkpatrick, CMJ; Metcalf, SCL; Zhang, M, 2021
)
1.08
" One key challenge of DFMO is its rapid renal clearance and the need for high and frequent drug dosing during treatment."( Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Bachmann, AS; Dowling, TC; Schultz, CR; Swanson, MA, 2021
)
2.06
"It is important to consider the effects of DDIs on the abrocitinib active moiety when making dosing recommendations."( Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Connell, CA; Dowty, ME; Le, VH; Malhotra, BK; O'Gorman, MT; Tatulych, S; Tripathy, S; Valdez, H; Wang, X; Winton, JA; Wouters, A; Yin, N, 2022
)
0.72
" Renal and biliary excretions and plasma concentration-time profiles of KYNA, pyridoxic acid (PDA), homovanillic acid (HVA), and coproporphyrin I (CP-I) were assessed in BDC monkeys dosed with either probenecid (PROB) at 100 mg/kg or the control vehicle."( Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys.
Hao, J; Lai, Y; Liu, R; Zhao, X, 2023
)
1.1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
uricosuric drugA gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (56)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency11.22020.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.13170.006038.004119,952.5996AID1159521
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
GLI family zinc finger 3Homo sapiens (human)Potency21.13170.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID743040
progesterone receptorHomo sapiens (human)Potency61.56600.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720692
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.42820.001530.607315,848.9004AID1224841; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.99480.000229.305416,493.5996AID1259244; AID588514; AID743075; AID743077; AID743079
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00140.023723.228263.5986AID588543
alpha-galactosidaseHomo sapiens (human)Potency50.11874.466818.391635.4813AID1467
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency28.73320.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency63.09570.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.22010.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency60.36080.042027.378961.6448AID743210; AID743228
ras-related protein Rab-9AHomo sapiens (human)Potency6.30960.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency4.73040.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency69.07820.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency69.07820.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Ki72.90000.03702.34107.3000AID679492
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki23.40001.60005.744010.0000AID680343; AID681746
Carbonic anhydrase 12Homo sapiens (human)Ki1.24500.00021.10439.9000AID1183833; AID1230150; AID1241138
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)509.90000.40002.75008.6000AID1209456
Solute carrier family 22 member 8Mus musculus (house mouse)IC50 (µMol)3.02003.02003.02003.0200AID1209730
Bile salt export pumpHomo sapiens (human)IC50 (µMol)428.20000.11007.190310.0000AID1209455; AID1449628; AID1473738
Carbonic anhydrase 1Homo sapiens (human)Ki10.00000.00001.372610.0000AID1183830; AID1230147; AID1241135
Carbonic anhydrase 2Homo sapiens (human)Ki0.43100.00000.72369.9200AID1183831; AID1230148; AID1241136
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)Ki221.00008.50008.50008.5000AID624642
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki74.40001.10004.51259.8000AID679970
Carbonic anhydrase 9Homo sapiens (human)Ki0.36000.00010.78749.9000AID1183832; AID1230149; AID1241137
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)10.12000.27004.53069.9000AID1649920; AID679324; AID681160; AID681331; AID682026
Solute carrier family 22 member 6Homo sapiens (human)Ki6.93670.03003.20437.8200AID678821; AID678999; AID679393
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)1,640.00000.18003.68578.8000AID681159
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki44.60000.84004.968210.0000AID679032
Solute carrier family 22 member 20Mus musculus (house mouse)Ki8.45571.10006.67899.1201AID360149
Solute carrier family 22 member 8Homo sapiens (human)IC50 (µMol)6.96504.93007.39009.9200AID1649921; AID678815
Solute carrier family 22 member 8Homo sapiens (human)Ki14.40330.04004.22979.0000AID678814; AID678987; AID681372
Solute carrier family 22 member 6Mus musculus (house mouse)Ki6.35480.40745.02179.4000AID360150
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Canalicular multispecific organic anion transporter 1Homo sapiens (human)Ki42.20004.70006.40508.1100AID680796
Solute carrier family 22 member 12Homo sapiens (human)IC50 (µMol)68.19500.02602.61527.3000AID329663; AID593714
Solute carrier organic anion transporter family member 1C1Mus musculus (house mouse)Ki293.00000.27001.11002.1500AID681369
Pannexin-1Mus musculus (house mouse)IC50 (µMol)150.00000.27005.135010.0000AID1772526
Solute carrier family 22 member 11Homo sapiens (human)IC50 (µMol)40.15002.03004.66507.3000AID1649922; AID678973
Solute carrier family 22 member 11Homo sapiens (human)Ki49.65000.20002.57716.1500AID678972; AID679295
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)1,700.00001.00004.446710.0000AID681158
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)IC50 (µMol)6.03006.03006.03006.0300AID678805
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Ki12.21503.09005.54009.1000AID679176; AID679290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)4,200.00000.00033.166210.0000AID1549790
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (116)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A9Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A9Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A9Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A9Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A9Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A9Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A9Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1-6Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1-6Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
response to ischemiaPannexin-1Homo sapiens (human)
monoatomic cation transportPannexin-1Homo sapiens (human)
calcium ion transportPannexin-1Homo sapiens (human)
ATP transportPannexin-1Homo sapiens (human)
positive regulation of interleukin-1 alpha productionPannexin-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionPannexin-1Homo sapiens (human)
response to ATPPannexin-1Homo sapiens (human)
oogenesisPannexin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionPannexin-1Homo sapiens (human)
calcium ion transmembrane transportPannexin-1Homo sapiens (human)
monoatomic anion transmembrane transportPannexin-1Homo sapiens (human)
cell-cell signalingPannexin-1Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 12Homo sapiens (human)
response to xenobiotic stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate transportSolute carrier family 22 member 12Homo sapiens (human)
cellular homeostasisSolute carrier family 22 member 12Homo sapiens (human)
cellular response to insulin stimulusSolute carrier family 22 member 12Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 12Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 12Homo sapiens (human)
renal urate salt excretionSolute carrier family 22 member 12Homo sapiens (human)
organic anion transportSolute carrier family 22 member 12Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A7Homo sapiens (human)
coumarin metabolic processUDP-glucuronosyltransferase 1A7Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A7Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A7Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A7Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A7Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A7Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A10Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A10Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 7Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 7Homo sapiens (human)
organic anion transportSolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 7Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (61)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A9Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A9Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A9Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A9Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A9Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
gap junction hemi-channel activityPannexin-1Homo sapiens (human)
protease bindingPannexin-1Homo sapiens (human)
signaling receptor bindingPannexin-1Homo sapiens (human)
structural molecule activityPannexin-1Homo sapiens (human)
monoatomic anion channel activityPannexin-1Homo sapiens (human)
calcium channel activityPannexin-1Homo sapiens (human)
ATP transmembrane transporter activityPannexin-1Homo sapiens (human)
protein bindingPannexin-1Homo sapiens (human)
leak channel activityPannexin-1Homo sapiens (human)
transmembrane transporter bindingPannexin-1Homo sapiens (human)
actin filament bindingPannexin-1Homo sapiens (human)
scaffold protein bindingPannexin-1Homo sapiens (human)
wide pore channel activityPannexin-1Homo sapiens (human)
urate transmembrane transporter activitySolute carrier family 22 member 12Homo sapiens (human)
PDZ domain bindingSolute carrier family 22 member 12Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A7Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A7Homo sapiens (human)
protein kinase C bindingUDP-glucuronosyltransferase 1A7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A7Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A7Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A7Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A7Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein kinase C bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 7Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A9Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A9Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A9Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1-6Homo sapiens (human)
intracellular membrane-bounded organelleUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
endoplasmic reticulumPannexin-1Homo sapiens (human)
endoplasmic reticulum membranePannexin-1Homo sapiens (human)
plasma membranePannexin-1Homo sapiens (human)
gap junctionPannexin-1Homo sapiens (human)
membranePannexin-1Homo sapiens (human)
blebPannexin-1Homo sapiens (human)
protein-containing complexPannexin-1Homo sapiens (human)
plasma membranePannexin-1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
membraneSolute carrier family 22 member 12Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 12Homo sapiens (human)
brush border membraneSolute carrier family 22 member 12Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 12Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A7Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A7Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A7Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
cytosolSolute carrier family 22 member 7Homo sapiens (human)
plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
membraneSolute carrier family 22 member 7Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (315)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID678815TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT3-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID680317TP_TRANSPORTER: efflux of 3uM mitoxantrone in the presence of Probenecid at 1mM in MCF7/R cells2004Cancer chemotherapy and pharmacology, May, Volume: 53, Issue:5
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
AID682073TP_TRANSPORTER: In vivo biliary excretion in vivo, biliary excretion of SDR and EHBR rat2003Pharmaceutical research, Jan, Volume: 20, Issue:1
Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1241137Inhibition of human carbonic anhydrase-9 incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Exploring new Probenecid-based carbonic anhydrase inhibitors: Synthesis, biological evaluation and docking studies.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID562100Chemosensitization of desethylamodiaquin against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID679324TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells2003Kidney international, Jan, Volume: 63, Issue:1
Urate transport via human PAH transporter hOAT1 and its gene structure.
AID682026TP_TRANSPORTER: inhibition of PHA uptake (PHA: 5uM) in hOAT1-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID427722Reversal of MRP1-mediated doxorubicin-resistance in human 2008/MRP1 cells assessed as reduction of doxorubicin IC50 percent by half2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1132622Natriuretic activity in chimpanzee assessed as change in Curate to Cinsulin ratio at 5 mg/kg, po1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
(Acylaryloxy)acetic acid diuretics. 2. (2-Alkyl-2-aryl-1-oxo-5-indanyloxy)acetic acids.
AID592682Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID680798TP_TRANSPORTER: inhibition of NEM-GS uptake (NEM-GS: 4 uM, Probenecid: <1000 uM) in membrane vesicles from MRP2-expressing Sf9 cells2000Molecular pharmacology, Apr, Volume: 57, Issue:4
Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions.
AID51590Compound was tested for the oral diuretic activity in chimpanzee at the dose 5 mg/kg expressed as excretion rate in microequiv of K+/min; Not tested1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 4. Indeno[5,4-b]furan-2-carboxylic acids.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681540TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 17 uM, Probenecid: 1000 uM) in Xenopus laevis oocytes1991Proceedings of the National Academy of Sciences of the United States of America, Dec-01, Volume: 88, Issue:23
Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID678973TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT4-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID1649924Tmax in human2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID624643Inhibition of 4-methylumbelliferone glucuronidation by human recombinant UGT1A102005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID681414TP_TRANSPORTER: inhibition of Homovanillic acid uptake (HVA: 0.2 uM, Probenecid: 1000 uM) in Xenopus laevis oocytes2003Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Apr, Volume: 23, Issue:4
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
AID680943TP_TRANSPORTER: inhibition of NEM-GS in the presence of Probenecid at a concentration of 1mM in membrane vesicles from MRP6-expressing Sf9 cells2002The Journal of biological chemistry, May-10, Volume: 277, Issue:19
Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6).
AID681797TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Probenecid: 200 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID678987TP_TRANSPORTER: inhibition of E1S uptake in OAT3-expressing S2 cells2001European journal of pharmacology, May-11, Volume: 419, Issue:2-3
Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID679523TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Probenecid: 100 uM) in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID678999TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells2001European journal of pharmacology, May-11, Volume: 419, Issue:2-3
Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters.
AID1549790Agonist activity at human TRPA1 expressed in CHO cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1241138Inhibition of human carbonic anhydrase-12 incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Exploring new Probenecid-based carbonic anhydrase inhibitors: Synthesis, biological evaluation and docking studies.
AID681160TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID562097Chemosensitization of primaquine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID562103Chemosensitization of mefloquine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID679176TP_TRANSPORTER: inhibition of PCG uptake in Oat3-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.
AID562096Chemosensitization of chloroquine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID679828TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in rOAT2-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681504TP_TRANSPORTER: increase in Calcein intracellular accumulation (Calcein: 0.5 uM, Probenecid: 2000 uM) in GLC4/Sb30 cells1999Biochemical and biophysical research communications, May-19, Volume: 258, Issue:3
Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681424TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Probenecid: 1000 uM) in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1549815Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 1 M by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID427727Reversal of MRP1-mediated doxorubicin resistance in doxorubicin co-incubated human 2008/MRP1 cells assessed as effect on doxorubicin accumulation at 500 uM after 120 mins by spectrofluorimetry2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID681369TP_TRANSPORTER: inhibition of L-T4 uptake in Oatp14-expressing HEK293 cells2004Endocrinology, Sep, Volume: 145, Issue:9
Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.
AID1772526Inhibition of mouse Panx-1 expressed in Xenopus laevis oocytes assessed as inhibition of membrane current cells held at -60 mV and voltage steps to +60 mV in presence of CBX measured by Whole cell voltage clamp assay relative to control2021European journal of medicinal chemistry, Nov-05, Volume: 223Design and synthesis of the first indole-based blockers of Panx-1 channel.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679395TP_TRANSPORTER: inhibition of PAH uptake (Probenecid: 200 uM) in OAT1-expressing HeLa cells1999The American journal of physiology, 02, Volume: 276, Issue:2
Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C.
AID679512TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in hOAT2-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID679916TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) (Taxol: 0.8 uM, Probenecid: 1000 u) in Caco-2 cells2001Pharmaceutical research, Feb, Volume: 18, Issue:2
A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
AID680695TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in the presence of Probenecid at 5mM in LLC-GA5-COL150 cells2004British journal of pharmacology, Dec, Volume: 143, Issue:7
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID1286187Binding affinity to pannexin 1 channel (unknown origin)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Inhibiting the Inflammasome: A Chemical Perspective.
AID427744Reversal of MRP1-mediated doxorubicin resistance in human 2008/MRP1 cells assessed as ratio of doxorubicin IC50 to doxorubicin IC50 in presence of compound at 50 uM2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID680672TP_TRANSPORTER: increase in saquinavir intracellular accumulation in the presence of Probenecid at 5mM in LLC-GA5-COL150 cells2004British journal of pharmacology, Dec, Volume: 143, Issue:7
Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624644Inhibition of 4-methylumbelliferone glucuronidation by human recombinant UGT1A62005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID588983Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OAT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID681123TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID593714Inhibition of human URAT1 expressed in xenopus oocyte assessed as inhibition of [14C]-labelled urate uptake after 60 mins by liquid scintillation counting2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID679492TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp2-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID680598TP_TRANSPORTER: increase in Etoposide intracellular accumulation (Etoposide: 2 uM, Probenecid: 5000 uM) in MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse2001The Journal of biological chemistry, Dec-07, Volume: 276, Issue:49
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
AID1649926Plasma protein binding in human2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID678982TP_TRANSPORTER: inhibition of EGCG in MRP2-expressing MDCKII cells2003Biochemical and biophysical research communications, Oct-10, Volume: 310, Issue:1
Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
AID679407TP_TRANSPORTER: inhibition of NEM-GS by Probenecid at a concentration of 1mM in membrane vesicles from MRP6-expressing Sf9 cells2002The Journal of biological chemistry, May-10, Volume: 277, Issue:19
Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6).
AID51594Compound was tested for the oral natriuretic activity in chimpanzee at the dose 5 mg/kg expressed as excretion rate in microequiv of Na+/min; Not tested1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 4. Indeno[5,4-b]furan-2-carboxylic acids.
AID624645Inhibition of 4-methylumbelliferone glucuronidation by human recombinant UGT1A72005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID624642Inhibition of 4-methylumbelliferone glucuronidation by human recombinant UGT1A12005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID562106Chemosensitization of pyrimethamine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID680171TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Probenecid: 1000 uM) in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID679290TP_TRANSPORTER: inhibition of E217betaG uptake in Oat3-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID679042TP_TRANSPORTER: inhibition of CDF uptake (CDF: 10 uM, Probenecid: 260 uM) in Mrp2-expressing Sf9 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.
AID680607TP_TRANSPORTER: inhibition of Estradiol-17beta-D-glucuronide uptake by Probenecid at a concentration of 10 uM in membrane vesicle from MRP8-expressing LLC-PK1 cells2005Molecular pharmacology, Feb, Volume: 67, Issue:2
Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID562109Chemosensitization of sesquiterpene dihydroartemisinin pyronaridine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID680343TP_TRANSPORTER: inhibition of PAH uptake in Oat1-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679540TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Probenecid: 1000 uM) in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID1230149Inhibition of human carbonic anhydrase 9 by stopped-flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID427713Increase in doxorubicin accumulation in doxorubicin-co-incubated human 2008/P cells at 3 uM after 120 mins by spectrofluorimetry2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624651Inhibition of acetaminophen glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID681020TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Probenecid: 1000 uM) in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID680796TP_TRANSPORTER: inhibition of SN-38 uptake in bile canalicular membrane vesicles2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:1
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
AID681158TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID1241136Inhibition of human carbonic anhydrase-2 incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Exploring new Probenecid-based carbonic anhydrase inhibitors: Synthesis, biological evaluation and docking studies.
AID679821TP_TRANSPORTER: In vivo biliary excretion of SDR rat2003Pharmaceutical research, Jan, Volume: 20, Issue:1
Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.
AID1219165Inhibition of OAT1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]PAH substrate uptake at 300 uM by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID562104Chemosensitization of quinine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID562098Chemosensitization of amodiaquin against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID681096TP_TRANSPORTER: inhibition of NEM-GS uptake (NEM-GS: 4 uM, Probenecid: <1000 uM) in membrane vesicles from MRP1-expressing Sf9 cells2000Molecular pharmacology, Apr, Volume: 57, Issue:4
Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions.
AID427723Reversal of MRP1-mediated doxorubicin resistance in doxorubicin co-incubated human 2008/MRP1 cells assessed as increase in doxorubicin accumulation at 3 uM after 120 mins by spectrofluorimetry relative to control2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1183833Inhibition of recombinant human carbonic anhydrase 12 after 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies.
AID681911TP_TRANSPORTER: inhibition of MTX uptake (MTX: 20 uM, Probenecid: 300 uM) in membrane vesicles from MRP4-expressing Sf9 cells2002Cancer research, Jun-01, Volume: 62, Issue:11
Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
AID1230147Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.
AID681868TP_TRANSPORTER: inhibition of cGMP uptake (cGMP: 5 uM, Probenecid: 50 uM) in membrane vesicles from MRP5-expressing V79 cells2000The Journal of biological chemistry, Sep-29, Volume: 275, Issue:39
The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1209723Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 1 mM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID679032TP_TRANSPORTER: inhibition of DNP-SG uptake in blie canalicular membrane vesicle from SD rat2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:1
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
AID681133TP_TRANSPORTER: inhibition of lactate uptake in Xenopus laevis oocytes1999The Biochemical journal, Aug-01, Volume: 341 ( Pt 3)Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes.
AID1230148Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1649922Inhibition of OAT4 (unknown origin)2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1209727Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins by Michaelis-Menten method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1209726Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins by Michaelis-Menten method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID681159TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID624646Inhibition of 4-methylumbelliferone glucuronidation by human recombinant UGT1A92005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID592683Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID680421TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Probenecid: 1000 uM) in membrane vesicles from MRP3-expressing HEK293 cells2001Cancer research, Oct-01, Volume: 61, Issue:19
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1286188Inhibition of organic anion transporter (unknown origin)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Inhibiting the Inflammasome: A Chemical Perspective.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID680632TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, Probenecid: 1000 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID679295TP_TRANSPORTER: inhibition of E1S uptake in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Jun, Volume: 301, Issue:3
Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors.
AID1549819Agonist activity at human TRPA1 Phe944Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 1 M by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID678972TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID427731Reversal of MRP1-mediated doxorubicin resistance in human 2008/MRP1 cells assessed as ratio of doxorubicin IC50 to doxorubicin IC50 in presence of compound at 0.5 uM2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID678821TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1219159Inhibition of OAT3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E-sul substrate uptake at 100 uM by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
AID329663Inhibition of human URAT1-mediated urate uptake in HEK293 cells2007Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 35, Issue:6
Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
AID1241135Inhibition of human carbonic anhydrase-1 incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Exploring new Probenecid-based carbonic anhydrase inhibitors: Synthesis, biological evaluation and docking studies.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1209728Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins by Michaelis-Menten method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID562101Chemosensitization of halofantrine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID1183832Inhibition of recombinant human carbonic anhydrase 9 after 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562108Chemosensitization of benzonaphthyridine pyronaridine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID232279Compound was tested for the ratio of clearance of urate to clearance of inulin levels at 5 mg/kg in Chimpanzee1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 4. Indeno[5,4-b]furan-2-carboxylic acids.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID681048TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Probenecid: 5 uM) in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID1209725Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 1 mM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1649925Half life in human2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681372TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID678805TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in rOAT3-expressing S2 cells2004Journal of pharmacological sciences, Feb, Volume: 94, Issue:2
Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.
AID1639440Toxicity in Wistar rat at 10 mg/kg, po administered via gavage2019Journal of natural products, 04-26, Volume: 82, Issue:4
Dihydrophenanthrenes from Juncus effusus as Inhibitors of OAT1 and OAT3.
AID593713Inhibition of human URAT1 expressed in xenopus oocyte assessed as inhibition of [14C]-labelled urate uptake at 50 uM after 60 mins by liquid scintillation counting2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
AID681746TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2000European journal of pharmacology, Dec-01, Volume: 409, Issue:1
Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562107Chemosensitization of methotrexate against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562105Chemosensitization of chlorcycloguanil against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID427745Reversal of MRP1-mediated doxorubicin resistance in human 2008/MRP1 cells assessed as ratio of doxorubicin IC50 to doxorubicin IC50 in presence of compound at 500 uM2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1209724Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 1 mM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1286189Cmax in po dosed human plasma at 500 mg measured after 48 hrs by HPLC analysis2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Inhibiting the Inflammasome: A Chemical Perspective.
AID682298TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Probenecid: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1183831Inhibition of recombinant human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies.
AID1549808Agonist activity at human TRPA1 Cys261Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 1 M by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID678846TP_TRANSPORTER: inhibition of (Ochratoxin A: 0.5uM) of Probenecid at a concentration of 1000uM in Oat5-expressing Xenopus oocytes2004American journal of physiology. Renal physiology, Aug, Volume: 287, Issue:2
Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney.
AID588984Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OAT32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID682159TP_TRANSPORTER: inhibition of cGMP uptake (cGAMP: 1 uM, Probenecid: 1000 uM) in membrane vesicles from MRP4-expressing Sf9 cells2002Journal of the American Society of Nephrology : JASN, Mar, Volume: 13, Issue:3
The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID682120TP_TRANSPORTER: inhibition of NEM-GS by Probenecid at a concentration of 1mM in membrane vesicles from MRP2-expressing Sf9 cells2002The Journal of biological chemistry, May-10, Volume: 277, Issue:19
Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6).
AID682217TP_TRANSPORTER: inhibition of CDF uptake (CDF: 10 uM, Probenecid: 260 uM) in Mrp3-expressing Sf9 cells2003The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2
Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.
AID681748TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S3 cells1999Kidney international, Dec, Volume: 56, Issue:6
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
AID1183830Inhibition of recombinant human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Selective inhibition of human carbonic anhydrases by novel amide derivatives of probenecid: synthesis, biological evaluation and molecular modelling studies.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID678814TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209729Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 1 mM after 10 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID679970TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing LLC-PK1 cells2001The Journal of pharmacology and experimental therapeutics, Jul, Volume: 298, Issue:1
Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1649921Inhibition of OAT3 (unknown origin)2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID51588Compound was tested for the oral diuretic activity in chimpanzee at the dose 5 mg/kg expressed as excretion rate in microequiv of Cl-/min; Not tested1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
(Acylaryloxy)acetic acid diuretics. 4. Indeno[5,4-b]furan-2-carboxylic acids.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID679389TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM, Probenecid: 1000 uM) in OAT1-expressing S2 cells2003Kidney international, Jan, Volume: 63, Issue:1
Urate transport via human PAH transporter hOAT1 and its gene structure.
AID1219166Inhibition of OAT4 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E-sul substrate uptake at 500 uM by liquid scintillation counting2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
AID1230150Inhibition of human carbonic anhydrase 12 by stopped-flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.
AID1132617Natriuretic activity in rat assessed as per cage at 9 mg/kg, po1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
(Acylaryloxy)acetic acid diuretics. 2. (2-Alkyl-2-aryl-1-oxo-5-indanyloxy)acetic acids.
AID682167TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Probenecid at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID681891TP_TRANSPORTER: inhibition of Taurocholate uptake in the presence of Probenecid at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells2003Hepatology (Baltimore, Md.), Aug, Volume: 38, Issue:2
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1656360Half life in potassium phosphate buffer by liquid chromatography-tandem mass spectrometry2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Designing around Structural Alerts in Drug Discovery.
AID679393TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID1209730Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID562099Chemosensitization of piperaquine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID329664Inhibition of human URAT1-mediated urate uptake in HEK293 cells at 2 uM2007Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 35, Issue:6
Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1649920Inhibition of OAT1 (unknown origin)2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacological urate-lowering approaches in chronic kidney disease.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681379TP_TRANSPORTER: inhibition of EGCG in MRP1-expressing MDCKII cells2003Biochemical and biophysical research communications, Oct-10, Volume: 310, Issue:1
Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
AID562102Chemosensitization of lumefantrine against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID678962TP_TRANSPORTER: inhibition of PGF2alpha uptake in OAT2-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Jun, Volume: 301, Issue:3
Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1345079Human Organic anion transporter 1 (Organic anion transporters (OATs))2003Kidney international, Jan, Volume: 63, Issue:1
Urate transport via human PAH transporter hOAT1 and its gene structure.
AID1346564Rat TRPV2 (Transient Receptor Potential channels)2007Neuroscience letters, Sep-25, Volume: 425, Issue:2
Transient receptor potential V2 expressed in sensory neurons is activated by probenecid.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,464)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902192 (63.28)18.7374
1990's481 (13.89)18.2507
2000's376 (10.85)29.6817
2010's325 (9.38)24.3611
2020's90 (2.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.40 (24.57)
Research Supply Index8.28 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index141.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials292 (7.97%)5.53%
Reviews151 (4.12%)6.00%
Case Studies119 (3.25%)4.05%
Observational4 (0.11%)0.25%
Other3,098 (84.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (58)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid in Healthy Participants [NCT05954624]Phase 148 participants (Anticipated)Interventional2023-07-10Recruiting
"Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers" [NCT03202511]Early Phase 115 participants (Actual)Interventional2017-06-23Completed
A Single Dose Oral Bioavailability Study of PanCytoVir™ Oral Suspension (100 mg/ml) 1000 mg Versus Probenecid 500 mg Tablets, 1000 mg (2 X 500 mg) in Healthy, Adult, Human Subjects Under Fasting Conditions [NCT06025344]Phase 114 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Phase 1, Randomized, Open-label, Crossover Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adult Subjects [NCT03105986]Phase 118 participants (Actual)Interventional2017-04-05Completed
An Open-label Phase I Study to Evaluate the Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects [NCT05881811]Phase 147 participants (Actual)Interventional2023-03-20Completed
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ASSESS SINGLE DOSE AND MULTIPLE DOSE PHARMACOKINETICS OF PF-04965842 AND ITS METABOLITES, AND THE EFFECT OF REPEAT-DOSE PROBENECID ON THE SINGLE DOSE PHARMACOKINETICS OF PF-04965842 AND ITS METABOLITES IN HEA [NCT03937258]Phase 112 participants (Actual)Interventional2019-05-21Completed
Evaluation of Renal Drug Transport in Healthy Volunteers [NCT00690014]10 participants (Actual)Interventional2006-08-31Completed
Overcoming Membrane Transporters to Improve CNS Drug Delivery [NCT01322009]Phase 1/Phase 214 participants (Actual)Interventional2011-03-31Completed
Expanded Access for the Use of Sulopenem Etzadroxil/Probenecid for the Treatment of Patients With Complicated Urinary Tract Infection Due to Quinolone-nonsusceptible Uropathogens [NCT04682834]0 participants Expanded AccessAvailable
TRPV2 Agonists in Fontan Circulation Patients [NCT03965351]Phase 48 participants (Actual)Interventional2017-03-21Completed
Pharmacologic Study of Oseltamivir in Healthy Volunteers [NCT00439530]Phase 121 participants (Actual)Interventional2006-11-30Completed
Randomized, 3-Way Crossover Bioequivalence Study of Single Dose Colchicine Tablets and Effect of Food [NCT01021020]Phase 128 participants (Actual)Interventional2007-09-30Completed
A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Ad [NCT05584657]Phase 32,229 participants (Actual)Interventional2022-10-18Active, not recruiting
An Open-label, Drug Interaction Study to Evaluate Safety, Pharmacokinetic, and Pharmacodynamic Effect of Oral Administration of AV-101 Alone and in Combination With Probenecid in Healthy Subjects [NCT05280054]Phase 124 participants (Anticipated)Interventional2021-12-23Recruiting
Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial [NCT01029782]Phase 2206 participants (Actual)Interventional2010-05-31Completed
A Phase I, Single-Center, Open-Label, Non-randomized, One-Sequence Crossover, Pharmacokinetic Interaction Study of the Combination Product VI-0521 (Phentermine Plus Topiramate) With Metformin, Sitagliptin or Probenecid in Healthy Subjects [NCT00842400]Phase 120 participants (Actual)Interventional2009-02-28Completed
HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol [NCT00000799]100 participants InterventionalCompleted
Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers [NCT01907373]Phase 412 participants (Actual)Interventional2009-08-31Completed
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE) [NCT01320722]Phase 3242 participants (Actual)Interventional2011-03-31Completed
Addition of Probenecid to Penicillin-V Therapy: an Open Label, Cross-over Study in Healthy Volunteers [NCT05082909]Phase 1/Phase 250 participants (Anticipated)Interventional2021-12-21Recruiting
A Three-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions (DDIs) Between DBPR108 and Warfarin Sodium/Digoxin/Probenecid in Healthy Subjects [NCT05045313]Phase 128 participants (Actual)Interventional2021-10-20Completed
An Open-Label, Fixed-Sequence Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects [NCT01428284]Phase 114 participants (Actual)Interventional2011-08-31Completed
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters [NCT05365451]Early Phase 132 participants (Actual)Interventional2022-04-11Completed
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS [NCT00002142]100 participants InterventionalCompleted
Multicenter, Randomized, Double-blind Parallel Group Pilot Study to Evaluate the Effect of Consuming a Combination of Probiotic Strains and a Combination of Plant Extracts and a Probiotic Strain on the Production and Nutritional Composition of Breast Milk [NCT04639232]60 participants (Anticipated)Interventional2021-01-30Not yet recruiting
Evaluating Transporter Protein Inhibitors in Patients With Epilepsy [NCT00610532]Phase 48 participants (Actual)Interventional2006-03-31Terminated(stopped due to Investigators decided not to continue)
Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) [NCT00000894]Phase 4300 participants InterventionalCompleted
A Study In Healthy Subjects To Assess The Effects Of Rifampicin Capsules and Probenecid Tablets On The Pharmacokinetic Profile Of Rongliflozin Capsules [NCT05497674]Phase 128 participants (Actual)Interventional2022-02-21Completed
A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of AT-527 in Adult Subjects With Normal and Impaired Renal Function Sub-Study: Effects of Probenecid on the Pharmacokinetics of AT-527 in Healthy [NCT05618314]Phase 136 participants (Anticipated)Interventional2022-10-17Recruiting
Probenecid as Pharmacotherapy for Alcohol Use Disorder [NCT04218357]Phase 134 participants (Anticipated)Interventional2020-12-02Recruiting
Phase I and Clinical Pharamcologic Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Combination With Probenecid in Adults With Advanced Solid Tumors [NCT00024245]Phase 10 participants Interventional2001-05-31Completed
Treatment of Veterans With Heart Failure With Reduced Ejection Fraction With Probenecid [NCT04551222]Phase 2/Phase 3120 participants (Anticipated)Interventional2021-06-09Recruiting
ANK-dependent ATP Efflux Causes Calcium Pyrophosphate Deposition in Cartilage [NCT02243631]Early Phase 18 participants (Actual)Interventional2014-10-15Completed
Phase 1 Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid (11C-PABA) [NCT05611905]30 participants (Anticipated)Observational2023-12-30Recruiting
[NCT00288158]Phase 260 participants (Actual)Interventional2008-09-30Completed
Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) [NCT00304434]Phase 448 participants (Anticipated)Interventional2005-02-28Completed
A Study to Investigate the Potential Impact of Organic Anion Transporter 3 Inhibition by Probenecid on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects [NCT01937026]Phase 118 participants (Actual)Interventional2013-09-30Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Probenecid vs Allopurinol [NCT04746989]294,878 participants (Actual)Observational2021-02-01Active, not recruiting
Initial Study on the Use of Probenecid as a Positive Inotrope for the Treatment of Systolic Heart Failure in Stable NYHA Class II to IV Patients [NCT01814319]Phase 220 participants (Actual)Interventional2013-03-31Completed
Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study [NCT01816646]Phase 16 participants (Actual)Interventional2013-09-30Completed
A Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS) [NCT00000945]24 participants InterventionalCompleted
A Phase 1, Open-Label, Non-Randomized, Fixed-Sequence Composite Study to Evaluate the Effects of Probenecid, Rifampin, and Verapamil on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects [NCT03296800]Phase 148 participants (Actual)Interventional2017-09-27Completed
A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability & Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women [NCT03354598]Phase 31,671 participants (Actual)Interventional2018-08-01Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults [NCT03358576]Phase 3674 participants (Actual)Interventional2018-09-18Completed
An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects [NCT03138759]Phase 116 participants (Actual)Interventional2017-02-27Completed
Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks [NCT00000670]16 participants InterventionalCompleted
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine [NCT00000706]12 participants InterventionalCompleted
The Effect of Potent Inhibitors of Drug Transporters (Verapamil, Rifampin, Cimetidine, Probenecid) on Pharmacokinetics of a Transporter Probe Drug Cocktail Consisting of Digoxin, Furosemide, Metformin and Rosuvastatin (an Open-label, Randomised, Crossover [NCT03307252]Phase 145 participants (Actual)Interventional2017-10-25Completed
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection [NCT05442983]Phase 275 participants (Actual)Interventional2022-07-12Completed
A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS [NCT00002437]Phase 248 participants InterventionalCompleted
A Phase I/II Study of Cidofovir for HIV-Infected Children With Invasive CMV (Cytomegalovirus) Disease [NCT00000881]Phase 10 participants (Actual)InterventionalWithdrawn
A Randomised, Open-label, Three-way Crossover Trial to Investigate the Effect of Rifampicin and Probenecid on Empagliflozin Pharmacokinetics in Healthy Male and Female Subjects [NCT01634100]Phase 118 participants (Actual)Interventional2012-06-30Completed
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults [NCT03357614]Phase 31,395 participants (Actual)Interventional2018-09-18Completed
A Rational Approach to the Identification of New Treatment Options to Prevent Congenital Syphilis: Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy [NCT05309928]Phase 120 participants (Anticipated)Interventional2023-08-29Recruiting
A Phase 1, Two-Part, Open-label Study in Healthy Adult Volunteers to Assess a Single Dose of Vadadustat as a Victim in Drug-Drug Interactions With Cyclosporine, Probenecid and Rifampin [NCT03801746]Phase 140 participants (Actual)Interventional2018-07-20Completed
Improvement of Reproductive Function in Men With Spinal Cord Injury (SCI) [NCT05903859]Phase 390 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Pharmacokinetics of SNAC in Healthy Subjects [NCT03466567]Phase 121 participants (Actual)Interventional2018-03-15Completed
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal in People With Chronic Pain Undergoing Voluntary Opioid Tapering: a Pilot Study [NCT04939623]Phase 240 participants (Anticipated)Interventional2023-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01021020 (3) [back to overview]Maximal Plasma Concentration (Cmax)
NCT01021020 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT01021020 (3) [back to overview]Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT01029782 (1) [back to overview]The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.
NCT01320722 (9) [back to overview]Angiotensin II (ATII) Concentration [Uric Acid]
NCT01320722 (9) [back to overview]Angiotensin II (ATII) Concentration [Vitamin D]
NCT01320722 (9) [back to overview]Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]
NCT01320722 (9) [back to overview]Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]
NCT01320722 (9) [back to overview]Plasma Renin Activity (PRA) [Uric Acid]
NCT01320722 (9) [back to overview]Plasma Renin Activity (PRA) [Vitamin D]
NCT01320722 (9) [back to overview]Change in Endothelium-Dependent Vasodilation (EDV)
NCT01320722 (9) [back to overview]Mean 24-Hour Ambulatory Blood Pressure (ABP)
NCT01320722 (9) [back to overview]Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping
NCT01322009 (2) [back to overview]Antioxidant Reserve
NCT01322009 (2) [back to overview]Number of Participants Who Experienced Adverse Events
NCT01634100 (3) [back to overview]Total Empagliflozin: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)
NCT01634100 (3) [back to overview]Total Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01634100 (3) [back to overview]Total Empa: Maximum Measured Concentration (Cmax)
NCT01937026 (2) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
NCT01937026 (2) [back to overview]PK: Area Under the Concentration Curve From Time 0 to Infinity [AUC (0-∞)] of Baricitinib
NCT02243631 (1) [back to overview]ATP Levels in Synovial Fluid
NCT03202511 (2) [back to overview]Plasma TFV AUC0-INF GMR
NCT03202511 (2) [back to overview]PBMC TFV-DP AUC GMR
NCT03296800 (5) [back to overview]T1/2 (Apparent Terminal Elimination Half-life)
NCT03296800 (5) [back to overview]Tmax (Time of Maximum Observed Plasma Concentration)
NCT03296800 (5) [back to overview]Urinary Glucose Excretion 0-48 hr
NCT03296800 (5) [back to overview]AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
NCT03296800 (5) [back to overview]Cmax (Maximum Observed Plasma Concentration)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T1 vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T2 vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T3 vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T4 vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Cimetidine + R1 (T3) vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Probenecid + R1 (T4) vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)
NCT03307252 (12) [back to overview]Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)
NCT03307252 (12) [back to overview]Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T1 vs. R1)
NCT03307252 (12) [back to overview]Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T2 vs. R1)
NCT03307252 (12) [back to overview]Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T3 vs. R1)
NCT03307252 (12) [back to overview]Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T4 vs. R1)
NCT03354598 (4) [back to overview]Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Overall Success
NCT03354598 (4) [back to overview]Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success
NCT03354598 (4) [back to overview]Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success
NCT03354598 (4) [back to overview]Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success
NCT03357614 (2) [back to overview]Percentage of Participants With Microbiologic Success
NCT03357614 (2) [back to overview]Percentage of Participants With Overall Success
NCT03358576 (2) [back to overview]Percentage of Participants With Clinical Success
NCT03358576 (2) [back to overview]Percentage of Participants With Clinical Success
NCT03965351 (6) [back to overview]Changes in Exercise Performance (VO2 Absolute) as Determined by Completing Four Graded Exercise Tests Utilizing a Cycle Ergometer Ramp Protocol; Pre and Post Study Drug and Placebo Administration.
NCT03965351 (6) [back to overview]Impact of Study Medication on Exercise Capacity (Indexed VO2 [ml/kg/Min] of Single Ventricle Patients.
NCT03965351 (6) [back to overview]Impact of Study Medication on the MRI Ejection Fraction of Single Ventricle Patients.
NCT03965351 (6) [back to overview]Impact of Study Medication on MRI Flow Rates of the Ventricles (Cardiac Output) in Single Ventricle Patients
NCT03965351 (6) [back to overview]Impact of Study Medication on MRI Strain Values in Single Ventricle Patients
NCT03965351 (6) [back to overview]Changes in End Diastolic and End Systolic Volume as Measured by Standard and Advanced MRI Parameters

Maximal Plasma Concentration (Cmax)

The maximum or peak concentration that colchicine reaches in the plasma. (NCT01021020)
Timeframe: serial pharmacokinetic blood samples collected pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose

Interventionpg/mL (Mean)
Colchicine 0.6 mg (Fasted)2,503.04
Colchicine (High-fat Meal)2,496.88
Colchicine 0.5 mg/ Probenecid 500 mg (Fasted)1,706.03

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable colchicine plasma concentration to the elimination rate constant. (NCT01021020)
Timeframe: serial pharmacokinetic blood samples collected pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose

Interventionpg-hr/mL (Mean)
Colchicine 0.6 mg (Fasted)14,112.52
Colchicine 0.6 mg (High-fat Meal)11,404.09
Colchicine 0.5 mg/ Probenecid 500 mg (Fasted)8,481.41

[back to top]

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable colchicine concentration (t), as calculated by the linear trapezoidal rule. (NCT01021020)
Timeframe: serial pharmacokinetic blood samples collected pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose

Interventionpg-hr/mL (Mean)
Colchicine 0.6 mg (Fasting)12,588.61
Colchicine 0.6 mg (High-fat Meal)10,490.95
Colchicine 0.5 mg/ Probenecid 500 mg (Fasting)8,090.05

[back to top]

The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid.

(NCT01029782)
Timeframe: 72 hours

InterventionParticipants (Count of Participants)
IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin6
Oral Cephalexin and Saline IV Plus Probenecid Placebo4

[back to top]

Angiotensin II (ATII) Concentration [Uric Acid]

ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test. (NCT01320722)
Timeframe: Week 8

Interventionpg/mL (Median)
Probenecid20.3
Allopurinol21.4
Placebo- Uric Acid19.1

[back to top]

Angiotensin II (ATII) Concentration [Vitamin D]

ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test. (NCT01320722)
Timeframe: Week 8

Interventionpg/mL (Mean)
Vitamin D19.5
Placebo- Vitamin D19.7

[back to top]

Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]

Change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF. (NCT01320722)
Timeframe: Week 8 (pre and post captopril)

InterventionmL/min per 1.73 m^2 (Mean)
Vitamin D35.7
Placebo- Vitamin D35.9

[back to top]

Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]

RPF in response to captopril iis a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF. (NCT01320722)
Timeframe: Week 8 (pre and post captopril)

InterventionmL/min per 1.73 m^2 (Median)
Probenecid33
Allopurinol36
Placebo- Uric Acid30

[back to top]

Plasma Renin Activity (PRA) [Uric Acid]

PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test. (NCT01320722)
Timeframe: Week 8

Interventionng/mL per hour (Median)
Probenecid0.4
Allopurinol0.3
Placebo- Uric Acid0.2

[back to top]

Plasma Renin Activity (PRA) [Vitamin D]

PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test. (NCT01320722)
Timeframe: Week 8

Interventionng/mL per hour (Mean)
Vitamin D0.36
Placebo- Vitamin D0.44

[back to top]

Change in Endothelium-Dependent Vasodilation (EDV)

Endothelial function was assessed by EDV using brachial artery ultrasonography. Measurements of brachial artery diameter were made under basal conditions and reactive hyperemia following ischaemic stimulus. A blood pressure cuff on the forearm was pumped up for 5 minutes then released. Images were taken at baseline and after reactive hyperemia (increased blood flow). The maximum diameter was determined by the investigator. Change in EDV was expressed as a percent of brachial luminal diameter calculated as post-ischaemic brachial artery diameter - pre-ischaemic brachial artery diameter/pre-ischaemic brachial artery diameter * 100. (NCT01320722)
Timeframe: Baseline and Week 8 (pre and post ischaemic stimulus)

,,,,
Interventionpercent of brachial luminal diameter (Mean)
BaselineWeek 8
Allopurinol7.66.2
Placebo- Uric Acid6.57.1
Placebo- Vitamin D7.96.8
Probenecid7.48.3
Vitamin D6.36.1

[back to top]

Mean 24-Hour Ambulatory Blood Pressure (ABP)

A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours. (NCT01320722)
Timeframe: Baseline and Week 8

,,,,
InterventionmmHg (Mean)
Overall Systolic Blood Pressure (SBP), BaselineOverall Diastolic Blood Pressure (DBP), BaselineAwake SBP, BaselineAsleep SBP, BaselineOverall SBP, Week 8Overall DBP, Week 8Awake SBP, Week 8Asleep SBP, Week 8
Allopurinol124.172.1126.7117.1123.772.0125.1118.6
Placebo- Uric Acid122.471.9125.5113.9122.972.6124.9116.2
Placebo- Vitamin D123.773.7126.4116.5124.774.7127.6117.4
Probenecid126.973.3130.0119.2125.273.8128.1116.2
Vitamin D120.471.6122.4113.9121.672.0124.2114.7

[back to top]

Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping

A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours. Nocturnal dipping is the percent change lower between the daytime and nighttime values. (NCT01320722)
Timeframe: Baseline and Week 8

,,,,
Interventionpercent change (Mean)
BaselineWeek 8
Allopurinol7.55.2
Placebo- Uric Acid9.46.9
Placebo- Vitamin D7.88.1
Probenecid8.49.2
Vitamin D7.37.5

[back to top]

Antioxidant Reserve

Antioxidant reserves in CSF and serum will be calculated in both treatment arms and compared. (NCT01322009)
Timeframe: Within 5 days of injury

Interventionreactive oxygen species scavenged (Mean)
Drug751
Placebo735

[back to top]

Number of Participants Who Experienced Adverse Events

"The number of patients experiencing one or more of the following adverse events:~Acute renal failure Anaphylaxis Acute respiratory distress syndrome Intracranial infection/abscess Arrhythmia, atrial Arrhythmia, ventricular Bradycardia Cardiac arrest Catheter positive culture Cerebrospinal fluid leak Decubitis Deep vein thrombosis Diabetes Insipidus Emesis Extraaxial hematoma Gastrointestinal bleed Gastritis Hematuria Hemorrhage, other Hemoperitonium Hemothorax Hepatitis Hydrocephalus Hypotension Hypoxemia Infection, other Intraparenchymal hemorrhage Intraventricular hemorrhage Meningitis/ventriculitis Multiorgan dysfunction syndrome Myocardial ischemia Pancreatitis Pericarditis Peritonitis Pneumothorax Pulmonary edema Pulmonary embolism Respiratory arrest Seizures Sepsis Syndrome of inappropriate antidiuretic hormone Transtentorial herniation Withdrawal of Life Support Other SAE causing re-hospitalization Other SAE" (NCT01322009)
Timeframe: 14 days after drug administration

Interventionparticipants (Number)
Drug0
Placebo2

[back to top]

Total Empagliflozin: Area Under the Curve 0 to Time of Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of total empagliflozin (empa) in plasma over the time interval from 0 extrapolated to the time of last the quantifiable data point. (NCT01634100)
Timeframe: 15 minutes (min) prior to the first dose and 20min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h and 72h after the first dose

Interventionnmol*h/L (Geometric Mean)
Empa Alone2200
Empa + Rifampicin3000
Empa + Probenecid3350

[back to top]

Total Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of total empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity. (NCT01634100)
Timeframe: 15 minutes (min) prior to the first dose and 20min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h and 72h after the first dose

Interventionnmol*h/L (Geometric Mean)
Empa Alone2240
Empa + Rifampicin3020
Empa + Probenecid3400

[back to top]

Total Empa: Maximum Measured Concentration (Cmax)

Maximum measured concentration of total empa in plasma, per period. (NCT01634100)
Timeframe: 15 minutes (min) prior to the first dose and 20min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h and 72h after the first dose

Interventionnmol/L (Geometric Mean)
Empa Alone301
Empa + Rifampicin527
Empa + Probenecid373

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

(NCT01937026)
Timeframe: Days 1 and 5: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 (Day 5 dosing only) hours postdose

Interventionnanograms/milliliter (ng/mL) (Geometric Mean)
Baricitinib36.2
Baricitinib + Probenecid37.3

[back to top]

PK: Area Under the Concentration Curve From Time 0 to Infinity [AUC (0-∞)] of Baricitinib

(NCT01937026)
Timeframe: Days 1 and 5: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 (Day 5 dosing only) hours postdose

Interventionnanograms*hour/milliliter (ng*h/mL) (Geometric Mean)
Baricitinib236
Baricitinib + Probenecid480

[back to top]

ATP Levels in Synovial Fluid

The investigators will measure levels of ATP in synovial fluid from patients with CPPD before and after treatment with probenecid compared to patients receiving no therapy. ATP levels are measured with a standard bioluminescent assay. (NCT02243631)
Timeframe: 5 days

Interventionnanomoles/ml (Mean)
Probenecid4.4
no Intervention31.4

[back to top]

Plasma TFV AUC0-INF GMR

The geometric mean ratio (GMR) of the plasma TFV area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose. (NCT03202511)
Timeframe: The first 72 hours of each phase.

Interventionng*h/mL (Least Squares Mean)
Treatment Phase8.75
Control Phase8.27

[back to top]

PBMC TFV-DP AUC GMR

The geometric mean ratio (GMR) of the PBMC TFV-DP area under the curve (AUC) comparing the test phase (T) to control phase (C) was assessed. PK samples were collected from 0 to 72 hours post-dose. (NCT03202511)
Timeframe: The first 72 hours of each phase.

Interventionfmol*h/10^6cells (Least Squares Mean)
Treatment Phase7.12
Control Phase7.38

[back to top]

T1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA). (NCT03296800)
Timeframe: Up to 48 hours

,,
Interventionhours (Geometric Mean)
Bexagliflozin aloneBexagliflozin + additional drug
Bexagliflozin/Probenecid12.09013.894
Bexagliflozin/Rifampin12.1905.318
Bexagliflozin/Verapamil10.70911.675

[back to top]

Tmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA). (NCT03296800)
Timeframe: Up to 48 hours

,,
Interventionhours (Median)
Bexagliflozin aloneBexagliflozin + additional drug
Bexagliflozin/Probenecid2.0003.000
Bexagliflozin/Rifampin2.0002.000
Bexagliflozin/Verapamil3.03.000

[back to top]

Urinary Glucose Excretion 0-48 hr

Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics. (NCT03296800)
Timeframe: 0 to 48 hours

,,,,,
Interventiong (Mean)
Pre-dose (-12 - 0 hours)0 - 12 hours post-dose12 - 24 hours post-dose24 - 36 hours post-dose36 - 48 hours post-dose0 - 24 hours post-dose0 - 48 hours post-dose
Bexagliflozin/Probenecid0.4725.9020.9222.109.5346.8278.44
Bexagliflozin/Rifampin0.1231.4015.7216.323.4147.1266.86
Bexagliflozin/Verapamil1.3731.4620.5120.944.7851.9777.69
Study 1: Bexagliflozin Alone0.0225.0421.2822.0411.1547.7381.67
Study 2: Bexagliflozin Alone0.0231.5019.4321.516.9950.9379.43
Study 3: Bexagliflozin Alone0.0231.1422.3024.5411.3153.4489.29

[back to top]

AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA). (NCT03296800)
Timeframe: Up to 48 hours

Interventionhr*ng/mL (Geometric Mean)
Study 1: Bexagliflozin Alone1118.741
Study 1: Bexagliflozin/Probenecid1583.188
Study 2: Bexagliflozin Alone698.254
Study 2: Bexagliflozin/Rifampin601.334
Study 3: Bexagliflozin Alone1025.101
Study 3: Bexagliflozin/Verapamil1003.931

[back to top]

Cmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA). (NCT03296800)
Timeframe: Up to 48 hours

Interventionng/mL (Geometric Mean)
Study 1: Bexagliflozin Alone161.675
Study 1: Bexagliflozin and Probenecid193.366
Study 2: Bexagliflozin Alone97.811
Study 2: Bexagliflozin and Rifampin117.001
Study 3: Bexagliflozin Alone159.355
Study 3: Bexagliflozin and Verapamil169.000

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T1 vs. R1)

AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
FurosemideMetforminRosuvastatin
Cocktail (R1)191.291365.8594.14
Verapamil + R1 (T1)176.441147.23116.80

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T2 vs. R1)

AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
FurosemideMetforminRosuvastatin
Cocktail (R1)191.291365.8594.14
Rifampin + R1 (T2)215.631482.76320.72

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T3 vs. R1)

AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
FurosemideMetforminRosuvastatin
Cimetidine + R1 (T3)202.172023.33148.32
Cocktail (R1)200.611540.21139.21

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T4 vs. R1)

AUC0-∞, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 extrapolated to infinity is presented. AUC0-∞ not displayed for Digoxin analyte as precision was considered non-sufficient. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
FurosemideMetforminRosuvastatin
Cocktail (R1)188.111330.47113.78
Probenecid + R1 (T4)489.281346.62244.94

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Cimetidine + R1 (T3) vs. R1)

AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cimetidine + R1 (T3)19.03196.392006.60139.54
Cocktail (R1)15.15194.051532.41129.90

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Probenecid + R1 (T4) vs. R1)

AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)13.52177.961321.20106.69
Probenecid + R1 (T4)14.44483.381331.83238.16

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)

AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)13.61176.851357.3487.29
Rifampin + R1 (T2)17.89211.821473.38303.81

[back to top]

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)

AUC0-tz, area under the concentration-time curve of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) in plasma over the time interval from 0 to the last quantifiable data point is presented. Geometric mean (gMean) presented here is an adjusted gMean and standard error (SE) presented is a geometric SE (gSE). (NCT03307252)
Timeframe: Samples were taken within 0:20 hour:minutes (hh:mm) prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole*hour/litre (nmol*h/L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)13.61176.851357.3487.29
Verapamil + R1 (T1)13.71165.801126.2298.98

[back to top]

Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T1 vs. R1)

Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole/ litre (nmol/ L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)1.1788.59223.786.84
Verapamil + R1 (T1)1.4284.32179.457.90

[back to top]

Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T2 vs. R1)

Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole/ litre (nmol/ L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)1.1788.59223.786.84
Rifampin + R1 (T2)2.55119.66251.3277.00

[back to top]

Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T3 vs. R1)

Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole/ litre (nmol/ L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cimetidine + R1 (T3)1.6597.69316.8313.21
Cocktail (R1)1.3593.23258.3311.30

[back to top]

Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T4 vs. R1)

Cmax, maximum measured concentration of the analytes: digoxin, furosemide, metformin, and rosuvastatin (at cocktail doses) is presented. gMean presented here is an adjusted gMean and SE presented is a gSE. (NCT03307252)
Timeframe: Samples were taken within 0:20 hh:mm prior to first study drug administration and at 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 11:00, 12:00, 24:00, 36:00, 47:00, 71:00 and 95:00 after drug administration.

,
InterventionNanomole/ litre (nmol/ L) (Geometric Mean)
DigoxinFurosemideMetforminRosuvastatin
Cocktail (R1)1.3090.00243.4910.11
Probenecid + R1 (T4)1.13110.64246.7843.29

[back to top]

Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Overall Success

Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen) (NCT03354598)
Timeframe: 12 +/- 1 day

Interventionpercentage of participants (Number)
Sulopenem-etzadroxil/Probenecid65.6
Ciprofloxacin67.9

[back to top]

Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success

Overall Success: Clinical Success (resolution of uncomplicated urinary tract infection (uUTI) symptoms present at study entry and no new symptoms) AND Microbiologic success (eradication of the baseline pathogen) (NCT03354598)
Timeframe: Day 12+/-1 day

Interventionpercentage of participants (Number)
Sulopenem-etzadroxil/Probenecid62.6
Ciprofloxacin36.0

[back to top]

Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success

Microbiologic success is defined as eradication of the baseline pathogen (<1000 Colony Forming Units (CFU)/mL) at the Test of Cure visit (NCT03354598)
Timeframe: Day 12+/-1 day

Interventionpercentage of participants (Number)
Sulopenem-etzadroxil/Probenecid74.1
Ciprofloxacin49.6

[back to top]

Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success

Overall Success is Clinical Success (resolution of uUTI symptoms present at study entry and no new uUTI symptoms) AND Microbiologic success (eradication of the baseline pathogen) (NCT03354598)
Timeframe: Day 12 +/- 1 day

Interventionpercentage of participants (Number)
Sulopenem-etzadroxil/Probenecid66.8
Ciprofloxacin78.6

[back to top]

Percentage of Participants With Microbiologic Success

Microbiologic success is defined as demonstrating <1000 CFU/mL of the baseline urpathogen by quantitative urine culture (NCT03357614)
Timeframe: Day 21 +/- 1 day

InterventionParticipants (Count of Participants)
Sulopenem316
Ertapenem343

[back to top]

Percentage of Participants With Overall Success

Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL) (NCT03357614)
Timeframe: Day 21 +/- 1 day

InterventionParticipants (Count of Participants)
Sulopenem301
Ertapenem325

[back to top]

Percentage of Participants With Clinical Success

Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions (NCT03358576)
Timeframe: Day 11-14 +/- 1 day

InterventionParticipants (Count of Participants)
Sulopenem208
Ertapenem227

[back to top]

Percentage of Participants With Clinical Success

Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions (NCT03358576)
Timeframe: Day 28 +/- 1 day

Interventionpercentage of participants (Number)
Sulopenem85.5
Ertapenem90.2

[back to top]

Changes in Exercise Performance (VO2 Absolute) as Determined by Completing Four Graded Exercise Tests Utilizing a Cycle Ergometer Ramp Protocol; Pre and Post Study Drug and Placebo Administration.

Determine if Fontan patients treated with probenecid for four weeks will experience improved exercise performance compared with four weeks of placebo as measured by a maximal graded exercise test. Participants will complete a graded maximal cycle ergometer test at each of their four study visits. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

Interventionml/min (Mean)
Probenecid40
Placebo70

[back to top]

Impact of Study Medication on Exercise Capacity (Indexed VO2 [ml/kg/Min] of Single Ventricle Patients.

Determine if there is a quantitative difference in indexed VO2 max when patients have been taking the study medication (probenecid) versus a placebo. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

Interventionml/kg/min (Median)
Probenecid1
Placebo1

[back to top]

Impact of Study Medication on the MRI Ejection Fraction of Single Ventricle Patients.

Determine if there is a quantitative difference in ejection fraction when patients are taking the study medication (probenecid) versus when they are taking a placebo. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

Interventionpercent of blood (Median)
Probenecid-1.2
Placebo-1.1

[back to top]

Impact of Study Medication on MRI Flow Rates of the Ventricles (Cardiac Output) in Single Ventricle Patients

Determine if there is a quantitative difference in cardiac output of single ventricle patients when taking the study medication (probenecid) versus taking a placebo. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

InterventionL/min (Median)
Probenecid0.51
Placebo-0.21

[back to top]

Impact of Study Medication on MRI Strain Values in Single Ventricle Patients

Determine if there is a quantitative difference in longitudinal, circumferential, and radial strain MRI values when subjects take the study medication (probenecid) versus a placebo. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

,
Interventionpercent (Median)
Longitudinal Strain, systoleCircumferential Strain, systoleRadial Strain, systoleLongitudinal strain, diastoleCircumferential strain, diastoleRadial strain, diastole
Placebo1.0-1.000.200.100.10
Probenecid-2.02.02.50.14-0.23-0.31

[back to top]

Changes in End Diastolic and End Systolic Volume as Measured by Standard and Advanced MRI Parameters

Determine if Fontan patients treated with probenecid for four weeks will experience increased systolic and diastolic function (as measured via standard and advanced MRI parameters) compared with four weeks of placebo. Participants will be assigned to either the placebo arm or study medication arm for the first four weeks. They will then undergo a four week wash out period. Finally, participants will be placed into the study arm that they were not assigned to in the first four weeks when they return for the last four weeks of study participation. There will be four MRI scans over the course of the 12 week study period. (NCT03965351)
Timeframe: Total time participation in the study will be twelve weeks. Four weeks on the placebo or study medication, four weeks of a washout period and another four weeks with the study medication or placebo.

,
Interventionml (Median)
End Diastolic VolumeEnd Systolic Volume
Placebo3.04.4
Probenecid3.33.0

[back to top]